

Neuropsychiatric symptoms in Alzheimer's disease

Alzheimer's and Dementia

7, 532-539

DOI: 10.1016/j.jalz.2011.05.2410

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prevention of Unnecessary Hospitalization for Patients With Dementia. JAMA - Journal of the American Medical Association, 2012, 307, 197.	7.4	27
2	Diffusion Tensor Imaging of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, 484-488.	1.8	63
3	Nonpharmacologic Management of Behavioral Symptoms in Dementia. JAMA - Journal of the American Medical Association, 2012, 308, 2020.	7.4	382
4	Behavioral Disturbance in Dementia. Current Psychiatry Reports, 2012, 14, 298-309.	4.5	63
5	Addressing the Alzheimer's disease crisis through better understanding, treatment, and eventual prevention of associated neuropsychiatric syndromes. , 2012, 8, 60-64.		23
6	Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms. Epilepsy and Behavior, 2013, 26, 343-351.	1.7	111
7	Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6890-6896.	2.2	20
8	Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease. Alzheimer's and Dementia, 2013, 9, S95-S104.e1.	0.8	102
9	Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. Alzheimer's and Dementia, 2013, 9, 602-608.	0.8	292
10	Subscale Validation of the Neuropsychiatric Inventory Questionnaire: Comparison of Alzheimer's Disease Neuroimaging Initiative and National Alzheimer's Coordinating Center Cohorts. American Journal of Geriatric Psychiatry, 2013, 21, 607-622.	1.2	42
11	Previously not recognized deletion in presenilin-1 (p.Leu174del.) in a patient with early-onset familial Alzheimer's disease. Neuroscience Letters, 2013, 544, 115-118.	2.1	8
12	Broadening the etiological discourse on Alzheimer's disease to include trauma and posttraumatic stress disorder as psychosocial risk factors. Journal of Aging Studies, 2013, 27, 218-224.	1.4	16
13	White matter abnormalities associated with Alzheimer's disease and mild cognitive impairment: a critical review of MRI studies. Expert Review of Neurotherapeutics, 2013, 13, 483-493.	2.8	68
14	Aripiprazole in the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2013, 14, 459-474.	1.8	46
15	The Cache County Study on Memory in Aging: Factors affecting risk of Alzheimer's disease and its progression after onset. International Review of Psychiatry, 2013, 25, 673-685.	2.8	51
16	Biomarkers of Vascular Risk, Systemic Inflammation, and Microvascular Pathology and Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 363-371.	2.6	73
17	The impact of neuropsychiatric symptoms on caregiver distress and quality of life in persons with dementia in an Asian tertiary hospital memory clinic. International Psychogeriatrics, 2013, 25, 1991-1999.	1.0	52
18	Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics, 2013, 25, 707-719.	1.0	43

#	ARTICLE	IF	CITATIONS
19	The Brazilian version of the Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity in dementia. <i>International Psychogeriatrics</i> , 2013, 25, 1503-1511.	1.0	24
20	Assessment of neuropsychiatric symptoms in dementia: Toward improving accuracy. <i>Dementia E Neuropsychologia</i> , 2013, 7, 244-251.	0.8	11
21	Plasma cortisol in Alzheimer's disease with or without depressive symptoms. <i>Medical Science Monitor</i> , 2013, 19, 681-689.	1.1	41
22	Neuropsychiatric symptoms (NPS) in patients with pure vascular dementia (VaD) and mixed dementia (MD) from a memory outpatient clinic in Southeast Brazil. <i>Dementia E Neuropsychologia</i> , 2013, 7, 263-268.	0.8	4
23	Correlation between neuropsychiatric symptoms and caregiver burden in a population-based sample from São Paulo, Brazil: A preliminary report. <i>Dementia E Neuropsychologia</i> , 2013, 7, 258-262.	0.8	7
24	Behavioral symptoms related to cognitive impairment. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1443.	2.2	86
25	Why looking at the whole hippocampus is not enough – a critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimer's disease diagnosis. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 95.	3.7	109
26	Assessing neuropsychiatric symptoms in people with dementia: a systematic review of measures. <i>International Psychogeriatrics</i> , 2014, 26, 1805-1848.	1.0	59
27	Behavioral and Psychological Symptoms in Alzheimer's Disease. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	75
29	The Role of the Occupational Therapist in the Management of Neuropsychiatric Symptoms of Dementia in Clinical Settings. <i>Occupational Therapy in Health Care</i> , 2014, 28, 4-20.	0.3	21
30	Factors associated with caregiver readiness to use nonpharmacologic strategies to manage dementia-related behavioral symptoms. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 93-102.	2.7	39
31	Psychiatric Disorders in Dementia. , 2014, , 271-324.		1
32	Neuropsychiatric symptoms in the prodromal stages of dementia. <i>Current Opinion in Psychiatry</i> , 2014, 27, 230-235.	6.3	53
33	Antipsychotic Doses Among Community-Dwelling Persons With Alzheimer Disease in Finland. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 435-440.	1.4	18
34	Total Cholesterol and Neuropsychiatric Symptoms in Alzheimer's Disease: The Impact of Total Cholesterol Level and Gender. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 300-309.	1.5	11
35	Unpacking the Evidence: Interventions for Reducing Behavioral and Psychological Symptoms in People with Dementia. <i>Physical and Occupational Therapy in Geriatrics</i> , 2014, 32, 294-309.	0.4	16
36	A Systematic Review of Strategies to Foster Activity Engagement in Persons With Dementia. <i>Health Education and Behavior</i> , 2014, 41, 70S-83S.	2.5	62
37	Personality Changes in Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2014, 28, 261-268.	1.3	15

#	ARTICLE	IF	CITATIONS
38	Psychotropic Drugs in Patients With Alzheimer's Disease: A Longitudinal Study by the Registry of Dementias of Girona (ReDeGi) in Catalonia, Spain. Journal of the American Medical Directors Association, 2014, 15, 497-503.	2.5	8
39	Anxiety Is Not Associated with the Risk of Dementia or Cognitive Decline: The Rotterdam Study. American Journal of Geriatric Psychiatry, 2014, 22, 1382-1390.	1.2	40
40	Neuropsychiatric symptoms in Alzheimer's disease are related to functional connectivity alterations in the salience network. Human Brain Mapping, 2014, 35, 1237-1246.	3.6	137
41	GSK3 β , CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 83-93.	4.8	121
42	Management of Neuropsychiatric Symptoms of Dementia in Clinical Settings: Recommendations from a Multidisciplinary Expert Panel. Journal of the American Geriatrics Society, 2014, 62, 762-769.	2.6	423
43	A Critical Analysis and Adaptation of a Clinical Practice Guideline for the Management of Behavioral Problems in Residents with Dementia in Long-Term Care. Nursing Clinics of North America, 2014, 49, 105-113.	1.5	1
44	Old Worries and New Anxieties: Behavioral Symptoms and Mild Cognitive Impairment in a Population Study. American Journal of Geriatric Psychiatry, 2014, 22, 274-284.	1.2	32
45	Psychosis in Alzheimer's Disease. Biological Psychiatry, 2014, 75, 542-552.	1.3	153
46	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2691-2700.	3.1	70
47	Personality and risk of Alzheimer's disease: New data and meta-analysis. Alzheimer's and Dementia, 2014, 10, 179-186.	0.8	228
48	Long-Term Care in North Carolina. North Carolina Medical Journal, 2014, 75, 320-325.	0.2	1
49	Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 819-833.	2.6	53
50	The Impact of APOE Status on Relationship of Biomarkers of Vascular Risk and Systemic Inflammation to Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 40, 887-896.	2.6	15
51	Improving Dementia Care Through Behavioral Interventions. North Carolina Medical Journal, 2014, 75, 355-358.	0.2	3
52	Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. International Psychogeriatrics, 2015, 27, 2059-2067.	1.0	22
53	A Review of Pharmacological Treatments for Depression in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 48, 15-34.	2.6	7
54	Clinical and Demographic Factors Associated with the Cognitive and Emotional Efficacy of Regular Musical Activities in Dementia. Journal of Alzheimer's Disease, 2015, 49, 767-781.	2.6	39
55	Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer's Disease. Harvard Review of Psychiatry, 2015, 23, 377-393.	2.1	33

#	ARTICLE	IF	CITATIONS
56	Evaluation of a hospital-based day-structuring exercise programme on exacerbated behavioural and psychological symptoms in dementia - the exercise carousel: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 228.	1.6	9
57	Caregiver report versus clinician impression: disagreements in rating neuropsychiatric symptoms in Alzheimer's disease patients. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 1230-1237.	2.7	29
58	No pain, functional gain. <i>Pain</i> , 2015, 156, 1377-1378.	4.2	2
59	Psychological and Behavioral Disorders in Dementia. <i>International Journal of Emergency Mental Health</i> , 2015, 18, .	0.3	0
60	Alternative pharmacological treatment options for agitation in Alzheimer's disease. <i>Geriatric Care</i> , 2015, 1, .	0.2	1
61	Alzheimer's Disease associated with Psychiatric Comorbidities. <i>Anais Da Academia Brasileira De Ciencias</i> , 2015, 87, 1461-1473.	0.8	28
62	Comprehensive Gene- and Pathway-Based Analysis of Depressive Symptoms in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1197-1206.	2.6	33
63	Sleep-Wake Cycle Dysfunction in the TgCRND8 Mouse Model of Alzheimer's Disease: From Early to Advanced Pathological Stages. <i>PLoS ONE</i> , 2015, 10, e0130177.	2.5	40
64	Personal Strengths and Health Related Quality of Life in Dementia Caregivers from Latin America. <i>Behavioural Neurology</i> , 2015, 2015, 1-8.	2.1	31
65	Now Is the Time for True Reform of Mental Health Services. <i>JAMA Internal Medicine</i> , 2015, 175, 65.	5.1	0
66	Common Sense: Addressed to Geriatric Psychiatrists on the Subject of Behavioral and Psychological Symptoms of Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 1209-1213.	1.2	11
67	Non-pharmacological interventions as a best practice strategy in people with dementia living in nursing homes. A systematic review. <i>European Geriatric Medicine</i> , 2015, 6, 134-150.	2.8	61
68	Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. <i>Brain</i> , 2015, 138, 1036-1045.	7.6	67
69	Assessment and management of behavioral and psychological symptoms of dementia. <i>BMJ</i> , The, 2015, 350, h369-h369.	6.0	801
70	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 7.	6.2	47
71	Corpus Callosum Structure is Topographically Correlated with the Early Course of Cognition and Depression in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1097-1108.	2.6	16
72	Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. <i>International Psychogeriatrics</i> , 2015, 27, 181-197.	1.0	29
73	What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?. <i>Lancet Psychiatry</i> , the, 2015, 2, 756-764.	7.4	16

#	ARTICLE	IF	CITATIONS
74	Managing anxiety associated with neurodegenerative disorders. F1000prime Reports, 2015, 7, 05.	5.9	7
75	Cannabinoids in late-onset Alzheimer's disease. Clinical Pharmacology and Therapeutics, 2015, 97, 597-606.	4.7	38
76	Posterior Cortical Atrophy. Psychiatric Clinics of North America, 2015, 38, 211-220.	1.3	27
77	Exercise training for managing behavioral and psychological symptoms in people with dementia: A systematic review and meta-analysis. Ageing Research Reviews, 2015, 24, 274-285.	10.9	82
78	Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?. Cortex, 2015, 73, 36-61.	2.4	201
79	Neuropsychiatric effects of neurodegeneration of the medial versus lateral ventral prefrontal cortex in humans. Cortex, 2015, 73, 1-9.	2.4	24
80	Direct medical costs and source of cost differences across the spectrum of cognitive decline: A population-based study. Alzheimer's and Dementia, 2015, 11, 917-932.	0.8	70
81	Rescue of impaired late-phase long-term depression in a tau transgenic mouse model. Neurobiology of Aging, 2015, 36, 730-739.	3.1	37
82	Effects of cognitive stimulation on neuropsychiatric symptoms in elderly with Alzheimer's disease: A systematic review. Dementia & Neuropsychologia, 2016, 10, 178-184.	0.8	16
83	Drug Therapy for Behavioral and Psychological Symptoms of Dementia. Current Neuropharmacology, 2016, 14, 307-313.	2.9	29
84	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. Current Alzheimer Research, 2016, 13, 1145-1164.	1.4	50
85	Molecular Pathways Bridging Frontotemporal Lobar Degeneration and Psychiatric Disorders. Frontiers in Aging Neuroscience, 2016, 8, 10.	3.4	16
86	Reducing neuropsychiatric symptoms in persons with dementia and associated burden in family caregivers using tailored activities: Design and methods of a randomized clinical trial. Contemporary Clinical Trials, 2016, 49, 92-102.	1.8	56
87	Care-Delivery Interventions to Manage Agitation and Aggression in Dementia Nursing Home and Assisted Living Residents: A Systematic Review and Meta-analysis. Journal of the American Geriatrics Society, 2016, 64, 477-488.	2.6	59
88	Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings. Journal of Alzheimer's Disease, 2016, 51, 545-561.	2.6	26
89	Association of neuropsychiatric syndromes with global clinical deterioration in Alzheimer's disease patients. International Psychogeriatrics, 2016, 28, 779-786.	1.0	27
90	Sensor-based assessment of mobility-related behavior in dementia: feasibility and relevance in a hospital context. International Psychogeriatrics, 2016, 28, 1687-1694.	1.0	29
91	Construct validity and internal consistency of the neuropsychiatric inventory "nursing home (NPI-NH) in German nursing homes. International Psychogeriatrics, 2016, 28, 1017-1027.	1.0	26

#	ARTICLE	IF	CITATIONS
92	Different Patterns of Correlation between Grey and White Matter Integrity Account for Behavioral and Psychological Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 591-604.	2.6	15
93	Shared Genetic Risk Factors for Late-Life Depression and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1-15.	2.6	23
94	Occupational therapists' perspectives on using the remotivation process with clients experiencing dementia. <i>British Journal of Occupational Therapy</i> , 2016, 79, 92-101.	0.9	2
95	Feasibility of the Tailored Activity Program for Hospitalized (TAP-H) Patients With Behavioral Symptoms. <i>Gerontologist</i> , The, 2017, 57, gnw052.	3.9	23
96	Aberrant functional connectivity differentiates retrosplenial cortex from posterior cingulate cortex in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 44, 114-126.	3.1	63
97	Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 430-440.	4.5	32
98	Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible <i>tTa:APP</i> transgenic model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2016, 96, 171-185.	4.4	19
99	Considering new treatment paradigms for neuropsychiatric symptoms of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1031-1032.	0.8	2
100	Translation of the Care of Persons with Dementia in their Environments (COPE) intervention in a publicly-funded home care context: Rationale and research design. <i>Contemporary Clinical Trials</i> , 2016, 49, 155-165.	1.8	42
101	Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset Alzheimer's disease. <i>Human Brain Mapping</i> , 2016, 37, 4234-4247.	3.6	55
102	Charting the chemical space around the (iso)indoline scaffold, a comprehensive approach towards multitarget directed ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4211-4215.	2.2	3
103	EL ROL DE LA EVALUACIÓN NEUROPSICOLÓGICA EN EL DIAGNÓSTICO Y EN EL SEGUIMIENTO DE LAS DEMENCIAS. <i>Revista Médica Clínica Las Condes</i> , 2016, 27, 319-331.	0.2	3
104	Brain Regions Involved in Arousal and Reward Processing are Associated with Apathy in Alzheimer's Disease and Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 551-558.	2.6	30
105	Examining the Relationship Between Autobiographical Memory Impairment and Carer Burden in Dementia Syndromes. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 237-248.	2.6	20
106	Managing behavioral disturbances in a patient with dementia. <i>Nurse Practitioner</i> , 2016, 41, 50-54.	0.3	0
107	Improving Management of Behavioral and Psychological Symptoms of Dementia in Acute Care. <i>Nursing Administration Quarterly</i> , 2016, 40, 244-254.	1.5	17
108	Impact of caregiver readiness on outcomes of a nonpharmacological intervention to address behavioral symptoms in persons with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 1056-1063.	2.7	19
109	Speech and language impairments in dementia. <i>Journal of Applied Biomedicine</i> , 2016, 14, 97-103.	1.7	61

#	ARTICLE	IF	CITATIONS
110	Drugs related to monoamine oxidase activity. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 69, 112-124.	4.8	60
111	Biomarkers of aggression in dementia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 69, 125-130.	4.8	20
112	Microglial dysfunction connects depression and Alzheimer's disease. Brain, Behavior, and Immunity, 2016, 55, 151-165.	4.1	100
113	Depressive-like behavior observed with a minimal loss of locus coeruleus (LC) neurons following administration of 6-hydroxydopamine is associated with electrophysiological changes and reversed with precursors of norepinephrine. Neuropharmacology, 2016, 101, 76-86.	4.1	46
114	Trajectories of Neuropsychiatric Symptoms and Cognitive Decline in Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2016, 24, 70-80.	1.2	39
115	Disrupted-in-Schizophrenia-1 Attenuates Amyloid- β Generation and Cognitive Deficits in APP/PS1 Transgenic Mice by Reduction of β -Site APP-Cleaving Enzyme 1 Levels. Neuropsychopharmacology, 2016, 41, 440-453.	5.4	16
116	Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimer's and Dementia, 2016, 12, 195-202.	0.8	493
117	Effectiveness of Expanded Implementation of STAR-VA for Managing Dementia-Related Behaviors Among Veterans. Gerontologist, The, 2016, 56, 126-134.	3.9	44
118	Psychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA. International Journal of Geriatric Psychiatry, 2017, 32, 164-174.	2.7	66
119	Dysfunction of ventrolateral striatal dopamine receptor type 2-expressing medium spiny neurons impairs instrumental motivation. Nature Communications, 2017, 8, 14304.	12.8	46
120	Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 2017, 30, 26-49.	2.3	46
121	Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology, 2017, 88, 1814-1821.	1.1	61
122	Alterations in protein phosphorylation in the amygdala of the 5XFamilial Alzheimer's disease animal model. Journal of Pharmacological Sciences, 2017, 133, 261-267.	2.5	11
123	Elevated emotional contagion in a mouse model of Alzheimer's disease is associated with increased synchronization in the insula and amygdala. Scientific Reports, 2017, 7, 46262.	3.3	18
124	Detection and Management of Preexisting Cognitive Impairment in the Critical Care Unit. Critical Care Clinics, 2017, 33, 441-459.	2.6	5
125	Physical restraints and associations with neuropsychiatric symptoms and personal characteristics in residential care: a cross-sectional study. International Journal of Geriatric Psychiatry, 2017, 32, 1418-1424.	2.7	5
126	WeCareAdvisor, Alzheimer Disease and Associated Disorders, 2017, 31, 263-270.	1.3	28
127	Enhancing Communication in Adults with Dementia and Age-Related Hearing Loss. Seminars in Hearing, 2017, 38, 177-183.	1.2	13

#	ARTICLE	IF	CITATIONS
128	Neuropsychiatric Symptoms and Cognitive Impairment: Understanding the Importance of Co-Morbid Symptoms. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 141-153.	2.6	37
129	Distress Associated with Dementia-Related Psychosis and Agitation in Relation to Healthcare Utilization and Costs. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 1074-1082.	1.2	53
130	Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 387-393.	2.6	11
131	Background characteristics and treatment-related factors associated with treatment success or failure in a non-pharmacological intervention for dementia caregivers. <i>International Psychogeriatrics</i> , 2017, 29, 1005-1014.	1.0	6
132	Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series. <i>BMJ Open</i> , 2017, 7, e012759.	1.9	356
133	Mandibular movements and bite force in Alzheimer's disease before and after new denture insertion. <i>Journal of Oral Rehabilitation</i> , 2017, 44, 178-186.	3.0	11
134	Novel Vilazodone-Tacrine Hybrids as Potential Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease Accompanied with Depression: Design, Synthesis, and Biological Evaluation. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2708-2721.	3.5	32
135	Associations of Neuropsychiatric Symptoms and Antidepressant Prescription with Survival in Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 1076-1081.	2.5	26
136	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1 <i>H</i> -indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7483-7501.	6.4	25
137	Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 440-449.	3.7	240
138	A randomized trial of a web-based platform to help families manage dementia-related behavioral symptoms: The WeCareAdvisor. <i>Contemporary Clinical Trials</i> , 2017, 62, 27-36.	1.8	15
139	Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 483-493.	2.6	30
140	Trajectories of depressive symptoms and their relationship to the progression of dementia. <i>Journal of Affective Disorders</i> , 2017, 222, 146-152.	4.1	39
141	Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer's disease over a three-year period: Kuopio ALSOVA study. <i>International Psychogeriatrics</i> , 2017, 29, 1723-1733.	1.0	15
142	Behavior Symptoms in Primary Progressive Aphasia Variants. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2017, , 27-43.	0.3	1
143	Mild cognitive impairment and risk of depression and anxiety: A population-based study. <i>Alzheimer's and Dementia</i> , 2017, 13, 130-139.	0.8	72
144	Management of older adults with dementia who present to emergency services with neuropsychiatric symptoms. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1233-1240.	2.7	14
145	A supporting system for quick dementia screening using PIR motion sensor in smart home. , 2017, , .		6

#	ARTICLE	IF	CITATIONS
146	Dementia-related agitation: a review of non-pharmacological interventions and analysis of risks and benefits of pharmacotherapy. <i>Translational Psychiatry</i> , 2017, 7, e1250-e1250.	4.8	81
147	Development and pilot testing of a decision aid for the initiation of antipsychotic medications in persons with dementia in long-term care using a systematic approach: a study protocol. <i>BMJ Open</i> , 2017, 7, e018769.	1.9	8
148	Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAYFLOWER RoAD). <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1217-1228.	2.6	33
149	Physicochemical Properties for Potential Alzheimer's Disease Drugs. , 2017, , 59-82.		0
150	Computer-Based Training Programs for Older People with Mild Cognitive Impairment and/or Dementia. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 262.	2.0	48
151	Aerobic exercise improves quality of life, psychological well-being and systemic inflammation in subjects with Alzheimer's disease. <i>African Health Sciences</i> , 2017, 16, 1045.	0.7	62
152	Utility of the Neuropsychiatric Inventory Questionnaire (NPI-Q) in the assessment of a sample of patients with Alzheimer's disease in Chile. <i>Dementia E Neuropsychologia</i> , 2017, 11, 129-136.	0.8	30
153	Cognitive-Behavioral Therapy in Older Adults. , 2017, , 223-255.		28
154	Special Issue on mild behavioral impairment and non-cognitive prodromes to dementia. <i>International Psychogeriatrics</i> , 2018, 30, 167-169.	1.0	13
155	Commentary on Apathy as a Model for Investigating Behavioral and Psychological Symptoms in Dementia. <i>Journal of the American Geriatrics Society</i> , 2018, 66, S13-S16.	2.6	6
156	Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1445-1456.	2.4	41
157	Caregiver Reactions to Dementia Symptoms: Effects on Coping Repertoire and Mental Health. <i>Issues in Mental Health Nursing</i> , 2018, 39, 382-387.	1.2	5
158	The Progression of Neuropsychiatric Symptoms in Alzheimer's Disease During a Five-Year Follow-Up: Kuopio ALSOVA Study. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1367-1376.	2.6	24
159	Behavioural intervention to reduce resistance in those attending adult day care centres: <scp>PROCENDIAS</scp> study protocol for a randomized clinical trial. <i>Journal of Advanced Nursing</i> , 2018, 74, 1402-1411.	3.3	2
160	Targeting Behavioral Symptoms and Functional Decline in Dementia: A Randomized Clinical Trial. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 339-345.	2.6	71
161	Managing Behavioral and Psychological Symptoms of Dementia. <i>Psychiatric Clinics of North America</i> , 2018, 41, 127-139.	1.3	58
162	Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia. <i>Current Opinion in Psychiatry</i> , 2018, 31, 140-146.	6.3	15
163	Cracking novel shared targets between epilepsy and Alzheimer's disease: need of the hour. <i>Reviews in the Neurosciences</i> , 2018, 29, 425-442.	2.9	16

#	ARTICLE	IF	CITATIONS
164	Behavioral and Neuropsychiatric Disorders in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 63, 899-910.	2.6	40
165	Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, S313-S327.	2.6	31
166	The stability of neuropsychiatric subsyndromes in Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 880-888.	0.8	24
167	Association of the Centers for Medicare & Medicaid Services' National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014. JAMA Internal Medicine, 2018, 178, 640.	5.1	90
168	Outcomes of a Two-Component Intervention on Behavioral Symptoms in Persons With Dementia and Symptom Response in Their Caregivers. Journal of Applied Gerontology, 2018, 37, 570-594.	2.0	8
169	Quality of Life in relation to neuropsychiatric symptoms in Alzheimer's disease: 5-year prospective ALSOVA cohort study. International Journal of Geriatric Psychiatry, 2018, 33, 47-57.	2.7	57
170	Differential associations between sensory loss and neuropsychiatric symptoms in adults with and without a neurocognitive disorder. International Psychogeriatrics, 2018, 30, 261-272.	1.0	9
171	A systematic review of non-pharmacological treatments for apathy in dementia. International Journal of Geriatric Psychiatry, 2018, 33, e177-e192.	2.7	52
172	Neuropsychiatric symptoms as risk factors of dementia in a Mexican population: A 10/66 Dementia Research Group study. Alzheimer's and Dementia, 2018, 14, 271-279.	0.8	35
173	Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer's disease. International Psychogeriatrics, 2018, 30, 103-113.	1.0	99
174	Self-reported personality traits are prospectively associated with proxy-reported behavioral and psychological symptoms of dementia at the end of life. International Journal of Geriatric Psychiatry, 2018, 33, 489-494.	2.7	21
175	Noncognitive Behavioral Changes Associated With Alzheimer's Disease: Implications of Neuroimaging Findings. Journal of Neuropsychiatry and Clinical Neurosciences, 2018, 30, 14-21.	1.8	20
176	Alzheimer Disease. Journal for Nurse Practitioners, 2018, 14, 129-135.	0.8	64
177	Animal-assisted intervention for individuals with cognitive impairment: A meta-analysis of randomized controlled trials and quasi-randomized controlled trials. Psychiatry Research, 2018, 260, 418-427.	3.3	41
178	Reliability and Validity of the Care Plan Checklist for Evidence of Person-Centered Approaches for Behavioral and Psychological Symptoms Associated With Dementia. Journal of the American Medical Directors Association, 2018, 19, 613-618.	2.5	16
179	Relationship between the number of behavioral symptoms in dementia and caregiver distress: what is the tipping point?. International Psychogeriatrics, 2018, 30, 1099-1107.	1.0	43
180	Crosstalk between endoplasmic reticulum stress and brain inflammation in Alzheimer's disease. Neuropharmacology, 2018, 136, 350-360.	4.1	61
181	Temporal Associations between Caregiving Approach, Behavioral Symptoms and Observable Indicators of Aspiration in Nursing Home Residents with Dementia. Journal of Nutrition, Health and Aging, 2018, 22, 400-406.	3.3	25

#	ARTICLE	IF	CITATIONS
182	Brain Perfusion Correlates of Apathy in Alzheimer's Disease. <i>Dementia and Neurocognitive Disorders</i> , 2018, 17, 50.	1.4	8
183	â€œThis Condition isn't Going to get any Better so I can't see why we're Prolonging itâ€ Risks and Benefits of using Empirical Research to Inform Normative Decisions Concerning End-of-Life Care. <i>Journal of Disability and Religion</i> , 2018, 22, 283-297.	0.3	1
184	Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimerâ€™s Disease: A Case Report. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1363-1369.	2.6	5
185	Adaptive interaction as a method of non-verbal communication in individuals with dementia. <i>Practice Nursing</i> , 2018, 29, 176-180.	0.1	1
186	Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimerâ€™s disease: a network meta-analysis of 41 randomized controlled trials. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 126.	6.2	97
187	Pharmacologic management of behavioral and psychological symptoms of major neurocognitive disorder. <i>Mental Health Clinician</i> , 2018, 8, 284-293.	1.0	11
188	Radiomic Features of Hippocampal Subregions in Alzheimerâ€™s Disease and Amnesic Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 290.	3.4	86
189	Rehabilitation to live better with dementia. <i>Geriatrics and Gerontology International</i> , 2018, 18, 1529-1536.	1.5	35
190	Effects of Physical Exercise on Depressive Symptoms in Patients With Cognitive Impairment. <i>Journal of Nervous and Mental Disease</i> , 2018, 206, 809-823.	1.0	22
191	Cerebrospinal Fluid Orexin Levels and Nocturnal Sleep Disruption in Alzheimerâ€™s Disease Patients Showing Neuropsychiatric Symptoms. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 993-999.	2.6	22
192	Neuropathologic Correlates of Psychiatric Symptoms in Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 115-126.	2.6	133
193	Multinutrient Intervention in the Prevention and Treatment of Dementia. , 2018, , 341-351.		2
194	People with dementia getting lost in Australia: Dementiaâ€related missing person reports in the media. <i>Australasian Journal on Ageing</i> , 2018, 37, E97-E103.	0.9	12
195	Neuropsychiatric Symptoms of Major or Mild Neurocognitive Disorders. , 2018, , 467-494.		0
196	The cholinergic system in the pathophysiology and treatment of Alzheimerâ€™s disease. <i>Brain</i> , 2018, 141, 1917-1933.	7.6	1,008
197	Imaging Care Requirements: Use of Functional Neuroimaging to Predict Dementia Caregiver Burden. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 8, 180-189.	1.3	0
198	Increased risk of dementia in patients with Schizophrenia: A population-based cohort study in Taiwan. <i>European Psychiatry</i> , 2018, 53, 7-16.	0.2	32
199	Neuropsychiatric Symptoms and Caregiver Burden in Individuals With Alzheimerâ€™s Disease: The TEAM-AD VA Cooperative Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2018, 31, 177-185.	2.3	39

#	ARTICLE	IF	CITATIONS
200	Dementia Care at End of Life: Current Approaches. <i>Current Psychiatry Reports</i> , 2018, 20, 50.	4.5	20
201	Effect of the WeCareAdvisor [®] on family caregiver outcomes in dementia: a pilot randomized controlled trial. <i>BMC Geriatrics</i> , 2018, 18, 113.	2.7	45
202	mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2226.	4.1	84
203	Early Life Stress-Related Elevations in Reaction Time Variability Are Associated with Brain Volume Reductions in HIV+ Adults. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 6.	2.0	10
204	Alzheimer's disease: Only prevention makes sense. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13005.	3.4	41
205	Suppression of Presymptomatic Oxidative Stress and Inflammation in Neurodegeneration by Grape-Derived Polyphenols. <i>Frontiers in Pharmacology</i> , 2018, 9, 867.	3.5	29
206	Cognitive Therapy for Dementia Patients: A Systematic Review. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 46, 1-26.	1.5	48
207	Support vector machine-based classification of neuroimages in Alzheimer's disease: direct comparison of FDG-PET, rCBF-SPECT and MRI data acquired from the same individuals. <i>Revista Brasileira De Psiquiatria</i> , 2018, 40, 181-191.	1.7	29
208	Planning for an uncertain future in progressive neurological disease: a qualitative study of patient and family decision-making with a focus on eating and drinking. <i>BMC Neurology</i> , 2018, 18, 115.	1.8	21
209	Can nonalcoholic beer, silicon and hops reduce the brain damage and behavioral changes induced by aluminum nitrate in young male Wistar rats?. <i>Food and Chemical Toxicology</i> , 2018, 118, 784-794.	3.6	9
210	An intervention to reduce neuropsychiatric symptoms and caregiver burden in dementia: preliminary results from a randomized trial of the tailored activity program "outpatient version. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1301-1307.	2.7	45
211	Assessing mild behavioral impairment with the mild behavioral impairment checklist in people with subjective cognitive decline. <i>International Psychogeriatrics</i> , 2019, 31, 231-239.	1.0	80
212	When Less is More, but Still Not Enough: Why Focusing on Limiting Antipsychotics in People With Dementia Is the Wrong Policy Imperative. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 1074-1079.	2.5	49
213	Neurocognitive Disorders in Old Age: Alzheimer's Disease, Frontotemporal Dementia, Dementia with Lewy Bodies, and Prion and Infectious Diseases. , 2019, , 251-298.		2
214	Activities of mitochondrial respiratory chain complexes in platelets of patients with Alzheimer's disease and depressive disorder. <i>Mitochondrion</i> , 2019, 48, 67-77.	3.4	40
215	Translational approach to apathy-like behavior in mice: From the practical point of view. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 685-689.	1.8	2
216	Therapeutic Targeting of Casein Kinase 1 β in an Alzheimer's Disease Mouse Model. <i>Journal of Proteome Research</i> , 2019, 18, 3383-3393.	3.7	25
217	Management of Behavioral and Psychological Symptoms of Dementia. <i>Current Psychiatry Reports</i> , 2019, 21, 66.	4.5	148

#	ARTICLE	IF	CITATIONS
218	Self-Reported Personality Traits and Informant-Rated Cognition: A 10-Year Prospective Study. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 181-190.	2.6	10
219	Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-AD Mice. <i>Frontiers in Pharmacology</i> , 2019, 10, 1044.	3.5	33
220	Unmet Needs in Pharmacological Treatment of Apathy in Alzheimer's Disease: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 1108.	3.5	14
221	Tau and Amyloid- β Pathology in Japanese Forensic Autopsy Series Under 40 Years of Age: Prevalence and Association with APOE Genotype and Suicide Risk. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 641-652.	2.6	8
222	Cerebrospinal Fluid Correlates of Neuropsychiatric Symptoms in Patients with Alzheimer's Disease/Mild Cognitive Impairment: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 477-501.	2.6	25
223	Altered Cingulate Cortex Functional Connectivity in Normal Aging and Mild Cognitive Impairment. <i>Frontiers in Neuroscience</i> , 2019, 13, 857.	2.8	43
224	Differential Diagnosis of Cognitive Impairment in Bipolar Disorder: A Case Report. <i>Journal of Clinical Case Reports</i> , 2019, 09, .	0.0	0
225	Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer's disease: A systematic literature review. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 346-359.	6.1	29
226	Novel pyridazinone derivatives as butyrylcholinesterase inhibitors. <i>Bioorganic Chemistry</i> , 2019, 92, 103304.	4.1	8
227	Neuropsychiatric Manifestations of Cognitively Advanced Idiopathic Normal Pressure Hydrocephalus. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 8, 467-475.	1.3	9
228	Terapias no farmacológicas en demencia y agitación. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2019, 26, 43-49.	0.0	0
229	The Neuropsychiatric Inventory-Diary Rating Scale (NPI-Diary): A Method for Improving Stability in Assessing Neuropsychiatric Symptoms in Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 8, 306-320.	1.3	12
230	Meta-analysis of expression and methylation signatures indicates a stress-related epigenetic mechanism in multiple neuropsychiatric disorders. <i>Translational Psychiatry</i> , 2019, 9, 32.	4.8	11
231	Adopting a Diary to Support an Ecological Assessment of Neuropsychiatric Symptoms of Dementia. <i>Journal of Nutrition, Health and Aging</i> , 2019, 23, 614-616.	3.3	4
232	Collapsin response mediator protein 5 (CRMP5) causes social deficits and accelerates memory loss in an animal model of Alzheimer's disease. <i>Neuropharmacology</i> , 2019, 157, 107673.	4.1	14
233	Co-Creating Platform Governance Models Using Boundary Resources: a Case Study from Dementia Care Services. <i>Computer Supported Cooperative Work</i> , 2019, 28, 549-589.	2.9	4
235	Tau binding protein CAPON induces tau aggregation and neurodegeneration. <i>Nature Communications</i> , 2019, 10, 2394.	12.8	59
236	Alzheimer's disease and symbiotic microbiota: an evolutionary medicine perspective. <i>Annals of the New York Academy of Sciences</i> , 2019, 1449, 3-24.	3.8	45

#	ARTICLE	IF	CITATIONS
237	Overcoming a Bad Day: a Qualitative Look into the Dementia Caregiving Experiences of Mexican-Origin Women in East Los Angeles. <i>Journal of Cross-Cultural Gerontology</i> , 2019, 34, 373-384.	1.0	5
238	Unifying Hypothesis of Dopamine Neuron Loss in Neurodegenerative Diseases: Focusing on Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 123.	2.9	49
239	Age and sex differences in motivation and spatial working memory in 3xTg-AD mice in the Hebb-Williams maze. <i>Behavioural Brain Research</i> , 2019, 370, 111937.	2.2	16
240	Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 48.	6.2	14
241	Von Economo Neurons in Behavioral Variant Frontotemporal Dementia with Underlying Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 963-967.	2.6	10
242	Comparing the effect of the novel ionic cocrystal of lithium salicylate proline (LISPRO) with lithium carbonate and lithium salicylate on memory and behavior in female APPswe/PS1dE9 Alzheimer's mice. <i>Journal of Neuroscience Research</i> , 2019, 97, 1066-1080.	2.9	7
243	Effect of depressive disorder on cognitive decline. <i>Archives of Gerontology and Geriatrics</i> , 2019, 83, 211-216.	3.0	5
244	Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USA. <i>Drugs in R and D</i> , 2019, 19, 93-115.	2.2	39
245	Impact of three dementia-related behaviors on caregiver depression: The role of rejection of care, aggression, and agitation. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 966-973.	2.7	13
246	TREATMENT EFFECTS OF VORTIOXETINE ON COGNITIVE FUNCTIONS IN MILD ALZHEIMER'S DISEASE PATIENTS WITH DEPRESSIVE SYMPTOMS: A 12 MONTH, OPEN-LABEL, OBSERVATIONAL STUDY. <i>Journal of prevention of Alzheimer's disease, The</i> , 2019, 6, 1-6.	2.7	23
247	Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's Coordinating Centers volunteers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 333-339.	2.4	95
248	Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study. <i>Neurological Sciences</i> , 2019, 40, 1377-1382.	1.9	27
249	Association Between CSF Beta-Amyloid and Apathy in Early-Stage Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019, 32, 164-169.	2.3	11
250	Neurocognitive Disorders and Neuropsychiatric Symptoms. , 2019, , 39-69.		0
251	On the central role of mitochondria dysfunction and oxidative stress in Alzheimer's disease. <i>Neurological Sciences</i> , 2019, 40, 1527-1540.	1.9	76
252	Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia. <i>Frontiers in Pharmacology</i> , 2019, 10, 1398.	3.5	17
253	APOE ε4/ε4 Is Associated with Aberrant Motor Behavior Through Both Lewy Body and Cerebral Amyloid Angiopathy Pathology in High Alzheimer's Disease Pathological Load. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 1077-1087.	2.6	6
254	Early Cognitive and Behavioral Deficits in Mouse Models for Tauopathy and Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 335.	3.4	28

#	ARTICLE	IF	CITATIONS
255	Neuropsychiatric Symptoms in Alzheimer's Disease Are the Main Determinants of Functional Impairment in Advanced Everyday Activities. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 381-392.	2.6	25
256	Comparison of the efficacy of gesture-verbal treatment and doll therapy for managing neuropsychiatric symptoms in older patients with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1308-1315.	2.7	20
257	Meditation on the Soles of the Feet Practice Provides Some Control of Aggression for Individuals with Alzheimer's Disease. <i>Mindfulness</i> , 2019, 10, 1232-1242.	2.8	11
258	Repetitive Transcranial Magnetic Stimulation Improves Executive Function and Music Rhythm. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 178-180.	1.8	1
259	Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimer's disease and schizophrenia: Insights from studies in patient populations and animal models. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 112-137.	6.1	56
260	Developing a Pain Intensity Measure for Persons with Dementia: Initial Construction and Testing. <i>Pain Medicine</i> , 2019, 20, 1078-1092.	1.9	11
261	A systematic review of electronic assistive technology within supporting living environments for people with dementia. <i>Dementia</i> , 2019, 18, 2371-2435.	2.0	49
262	Prevalence of delusions in drug-naïve Alzheimer disease patients: A meta-analysis. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1287-1293.	2.7	7
263	Caregivers' emotional distress due to neuropsychiatric symptoms of persons with amnesic mild cognitive impairment or Alzheimer's disease. <i>Aging and Mental Health</i> , 2020, 24, 423-430.	2.8	14
264	Are neuropsychiatric symptoms modifiable risk factors for cognitive decline in Alzheimer's disease and vascular dementia?. <i>British Journal of Psychiatry</i> , 2020, 216, 1-3.	2.8	11
265	Findings From a Prospective Randomized Controlled Trial of an Individualized Music Listening Program for Persons With Dementia. <i>Journal of Applied Gerontology</i> , 2020, 39, 567-575.	2.0	25
266	Effects of Inappropriate Sexual Behaviors and Neuropsychiatric Symptoms of Patients With Alzheimer Disease and Caregivers' Depression on Caregiver Burden. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 243-249.	2.3	7
267	Optimizing Prescribing of Antipsychotics in Long-Term Care (OPAL): A Stepped-Wedge Trial. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 381-387.e3.	2.5	6
268	A Fast and Low-Cost Repetitive Movement Pattern Indicator for Massive Dementia Screening. <i>IEEE Transactions on Automation Science and Engineering</i> , 2020, 17, 771-783.	5.2	7
269	Neuropsychiatric symptoms as predictors of conversion from MCI to dementia: a machine learning approach. <i>International Psychogeriatrics</i> , 2020, 32, 381-392.	1.0	29
270	Neuropsychiatric symptoms and activities of daily living in Alzheimer's disease: ALSOVA 5-year follow-up study. <i>International Psychogeriatrics</i> , 2020, 32, 741-751.	1.0	23
271	Psychotherapy and Cognitive Disorders. , 2020, , 139-149.		1
272	Seeking for potential pathogenic genes of major depressive disorder in the Gene Expression Omnibus database. <i>Asia-Pacific Psychiatry</i> , 2020, 12, e12379.	2.2	6

#	ARTICLE	IF	CITATIONS
273	Does the neuropsychiatric inventory predict progression from mild cognitive impairment to dementia? A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2020, 58, 101004.	10.9	17
274	The Specialized Early Care for Alzheimer's method of caring for people with dementia: an investigation of what works and how. <i>Scandinavian Journal of Caring Sciences</i> , 2020, 34, 736-744.	2.1	3
275	Physical exercise attenuates cognitive decline and reduces behavioural problems in people with mild cognitive impairment and dementia: a systematic review. <i>Journal of Physiotherapy</i> , 2020, 66, 9-18.	1.7	116
276	A cluster-randomized crossover trial of Montessori activities delivered by family carers to nursing home residents with behavioral and psychological symptoms of dementia. <i>International Psychogeriatrics</i> , 2020, 32, 347-358.	1.0	20
277	Methylphenidate and Rosmarinus officinalis improves cognition and regulates inflammation and synaptic gene expression in Aβ1-3-induced neurotoxicity mouse model. <i>Molecular Biology Reports</i> , 2020, 47, 7861-7870.	2.3	7
278	Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 131.	6.2	17
279	Endocannabinoid system alterations in Alzheimer's disease: A systematic review of human studies. <i>Brain Research</i> , 2020, 1749, 147135.	2.2	23
280	Cognitive Impairment in the 3xTg-AD Mouse Model of Alzheimer's Disease is Affected by Aβ2-ImmunoTherapy and Cognitive Stimulation. <i>Pharmaceutics</i> , 2020, 12, 944.	4.5	17
281	Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 153.	6.2	9
282	Cognitive Reserve, Leisure Activity, and Neuropsychological Profile in the Early Stage of Cognitive Decline. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 590607.	3.4	20
283	Effectiveness of online dementia caregivers training programs: A systematic review. <i>Geriatric Nursing</i> , 2020, 41, 921-935.	1.9	37
284	Family Relationships and Alzheimer's Disease: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1595-1608.	2.6	8
285	White matter hyperintensities and neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102367.	2.7	28
286	Palliative Care in Advanced Dementia. <i>Frontiers in Psychiatry</i> , 2020, 11, 699.	2.6	52
287	The Role of Caregivers' Sleep Problems in the Association between Behavioral Symptoms of Dementia and Caregiving Depression and Anxiety. <i>Behavioral Sleep Medicine</i> , 2021, 19, 640-651.	2.1	9
289	Amyloid PET imaging in clinical practice. <i>Practical Neurology</i> , 2020, 20, 451-462.	1.1	28
290	Alzheimer's Dementia. , 2020, , 1-19.		0
291	Primary Progressive Aphasia. , 2020, , 20-42.		1

#	ARTICLE	IF	CITATIONS
294	Parkinson's Disease Dementia. , 2020, , 95-132.		0
295	Huntington's Disease. , 2020, , 133-166.		0
304	Memantine, Donepezil, or Combination Therapy—What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis. Brain and Behavior, 2020, 10, e01831.	2.2	55
305	Considering Psychodynamic Therapy for Older Adults. Psychodynamic Psychiatry, 2020, 48, 152-162.	0.3	1
306	THE SARS-COV-2 PANDEMIC AND THE BRAVE NEW DIGITAL WORLD OF ENVIRONMENTAL ENRICHMENT TO PREVENT BRAIN AGING AND COGNITIVE DECLINE. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-5.	2.7	7
307	Mental Health Status of Psychogeriatric Patients During the 2019 New Coronavirus Disease (COVID-19) Pandemic and Effects on Caregiver Burden. Frontiers in Psychiatry, 2020, 11, 578672.	2.6	24
308	Implementing a Reablement Intervention, "Care of People With Dementia in Their Environments (COPE)" A Hybrid Implementation-Effectiveness Study. Gerontologist, The, 2021, 61, 965-976.	3.9	17
309	More evidence for etiologic heterogeneity of dementia in the oldest-old: a Precision Medicine approach is needed to move treatment development forward. International Psychogeriatrics, 2020, 32, 563-565.	1.0	0
310	Verapamil and Alzheimer's Disease: Past, Present, and Future. Frontiers in Pharmacology, 2020, 11, 562.	3.5	16
311	Paroxetine ameliorates prodromal emotional dysfunction and late-onset memory deficit in Alzheimer's disease mice. Translational Neurodegeneration, 2020, 9, 18.	8.0	12
312	In vivo MRI Structural and PET Metabolic Connectivity Study of Dopamine Pathways in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 75, 1003-1016.	2.6	23
313	Insula and Amygdala Atrophy Are Associated With Functional Impairment in Subjects With Presbycusis. Frontiers in Aging Neuroscience, 2020, 12, 102.	3.4	20
314	A contextual model of care for persons with dementia. , 2020, , 245-269.		1
315	Neuropsychiatric Aspects of Alzheimer Dementia. Psychiatric Clinics of North America, 2020, 43, 383-397.	1.3	3
316	The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer's Disease During the COVID-19 Crisis. Journal of Alzheimer's Disease, 2020, 76, 41-47.	2.6	115
317	A Critical Review of Behavioral and Emotional Disinhibition. Journal of Nervous and Mental Disease, 2020, 208, 344-351.	1.0	7
318	Resting-state fMRI analysis in apathetic Alzheimer's disease. Diagnostic and Interventional Radiology, 2020, 26, 363-369.	1.5	12
319	Altered phobic reactions in frontotemporal dementia: A behavioural and neuroanatomical analysis. Cortex, 2020, 130, 100-110.	2.4	4

#	ARTICLE	IF	CITATIONS
320	Physical and Pharmacological Restraints in Hospital Care: Protocol for a Systematic Review. <i>Frontiers in Psychiatry</i> , 2019, 10, 921.	2.6	13
321	Shared genetic etiology underlying Alzheimer's disease and major depressive disorder. <i>Translational Psychiatry</i> , 2020, 10, 88.	4.8	45
322	Steps Towards Developing Effective Treatments for Neuropsychiatric Disturbances in Alzheimer's Disease: Insights From Preclinical Models, Clinical Data, and Future Directions. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 56.	3.4	11
323	Shared genetic etiology underlying late-onset Alzheimer's disease and posttraumatic stress syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, 1280-1292.	0.8	15
324	Virtual reality and dementia: A bibliometric analysis. <i>European Journal of Psychiatry</i> , 2020, 34, 120-131.	1.3	16
325	Resident-to-resident aggression in Norwegian nursing homes: a cross-sectional exploratory study. <i>BMC Geriatrics</i> , 2020, 20, 222.	2.7	13
326	Ongoing research protocols for the pharmacological treatment of neuropsychiatric symptoms in dementia. <i>Journal of Frailty & Aging</i> , 2021, 10, 1-9.	1.3	4
327	Rosmarinus officinalis Essential Oil Improves Scopolamine-Induced Neurobehavioral Changes via Restoration of Cholinergic Function and Brain Antioxidant Status in Zebrafish (<i>Danio rerio</i>). <i>Antioxidants</i> , 2020, 9, 62.	5.1	30
328	Does Telehealth Delivery of a Dyadic Dementia Care Program Provide a Noninferior Alternative to Face-To-Face Delivery of the Same Program? A Randomized, Controlled Trial. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 673-682.	1.2	43
329	Neuroanatomical associations of depression, anxiety and apathy neuropsychiatric symptoms in patients with Alzheimer's disease. <i>Acta Neurologica Belgica</i> , 2021, 121, 1469-1480.	1.1	12
330	Neuropsychiatric symptoms as prognostic makers for the elderly with mild cognitive impairment: a meta-analysis. <i>Journal of Affective Disorders</i> , 2020, 271, 185-192.	4.1	18
331	Embarking on a memory assessment voices of older persons living with memory impairment. <i>Dementia</i> , 2021, 20, 717-733.	2.0	4
332	Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes. <i>European Journal of Epidemiology</i> , 2021, 36, 89-101.	5.7	26
333	Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021, 10, 1.	8.0	23
334	Neuropsychiatric Symptoms in Patients With Alzheimer's Disease During SARS-COV-2 Pandemic in Peru. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2021, 36, 153331752110390.	1.9	5
335	Potential of Naturally Derived Alkaloids as Multi-Targeted Therapeutic Agents for Neurodegenerative Diseases. <i>Molecules</i> , 2021, 26, 728.	3.8	43
336	Nanodelivery of oxiracetam enhances memory, functional recovery and induces neuroprotection following concussive head injury. <i>Progress in Brain Research</i> , 2021, 265, 139-230.	1.4	9
337	Psychoses Due to Medical Illness or Iatrogenesis. , 2021, , 125-141.		0

#	ARTICLE	IF	CITATIONS
338	Female dominance of both spatial cognitive dysfunction and neuropsychiatric symptoms in a mouse model of Alzheimer's disease. <i>Experimental Animals</i> , 2021, 70, 398-405.	1.1	4
339	Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. <i>Progress in Brain Research</i> , 2021, 265, 1-97.	1.4	8
340	Machine Learning Methods with Decision Forests for Parkinson's Detection. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 581.	2.5	30
341	Relation among Caregivers' Burden, Abuse and Behavioural Disorder in People with Dementia. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1263.	2.6	12
342	Sex differences in psychiatric disorders and their implication for dementia. , 2021, , 187-206.		0
343	Use of psychiatric medication in three Arctic nursing homes: association with dementia and psychiatric symptoms. <i>International Journal of Circumpolar Health</i> , 2021, 80, 1920252.	1.2	0
344	Neuropsychiatric Symptoms Assessment: Cross-cultural Adaptation and Validation of the Portuguese Abe's BPSD Score (ABS). <i>Clinical Gerontologist</i> , 2022, 45, 591-605.	2.2	1
345	Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases. <i>CNS and Neurological Disorders - Drug Targets</i> , 2021, 20, 430-450.	1.4	29
346	Frequency and Predictors of Traumatic Encephalopathy Syndrome in a Prospective Cohort of Retired Professional Athletes. <i>Frontiers in Neurology</i> , 2021, 12, 617526.	2.4	10
347	Group Music Intervention Using Percussion Instruments to Reduce Anxiety Among Elderly Male Veterans with Alzheimer Disease. <i>Medical Science Monitor</i> , 2021, 27, e928714.	1.1	5
348	Association of Dementia-Related Psychosis With Long-term Care Use and Death. <i>Neurology</i> , 2021, 96, e1620-e1631.	1.1	6
349	Modifiable, Non-Modifiable, and Clinical Factors Associated with Progression of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1-27.	2.6	27
350	Behavioural and psychological symptoms of dementia: a new framework for holistic understanding and non-pharmacological management. <i>BJ Psych Advances</i> , 2022, 28, 11-20.	0.7	10
351	Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals. <i>Translational Neurodegeneration</i> , 2021, 10, 11.	8.0	17
352	The Relationship Between Anxiety and Alzheimer's Disease1. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 171-177.	2.2	53
353	Pain in persons with dementia and the direct and indirect impacts on caregiver burden. <i>Geriatric Nursing</i> , 2021, 42, 366-371.	1.9	6
354	Cannabis Use in Older Adults: A Perspective. <i>Harvard Review of Psychiatry</i> , 2021, 29, 225-233.	2.1	12
355	Affective symptoms and regional cerebral tau burden in early-stage Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1050-1058.	2.7	10

#	ARTICLE	IF	CITATIONS
356	Late-Life Anxiety. , 2021, , 226-240.		0
357	Validation of a Brief Screen to Identify Persons With Dementia at Risk for Behavioral Problems. Journal of Applied Gerontology, 2021, 40, 073346482199652.	2.0	2
358	Phenotyping Neuropsychiatric Symptoms Profiles of Alzheimer's Disease Using Cluster Analysis on EEG Power. Frontiers in Aging Neuroscience, 2021, 13, 623930.	3.4	4
359	The Potential Role of Herpes Simplex Virus Type 1 and Neuroinflammation in the Pathogenesis of Alzheimer's Disease. Frontiers in Neurology, 2021, 12, 658695.	2.4	22
360	Mendelian randomization identifies blood metabolites previously linked to midlife cognition as causal candidates in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	35
362	Photobiomodulation Therapy for Dementia: A Systematic Review of Pre-Clinical and Clinical Studies. Journal of Alzheimer's Disease, 2021, 83, 1431-1452.	2.6	27
363	Impaired Knowledge of Social Norms in Dementia and Psychiatric Disorders: Validation of the Social Norms Questionnaire—Dutch Version (SNQ-NL). Assessment, 2021, , 107319112110082.	3.1	2
364	The role of Bcl-2 proteins in modulating neuronal Ca ²⁺ signaling in health and in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118997.	4.1	31
366	Physical exercise is effective for neuropsychiatric symptoms in Alzheimer's disease: a systematic review. Arquivos De Neuro-Psiquiatria, 2021, 79, 447-456.	0.8	5
367	MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimer's disease. BMC Neuroscience, 2021, 22, 39.	1.9	25
368	Prevalence of depression, anxiety, and apathy symptoms across dementia stages: A systematic review and meta-analysis. International Journal of Geriatric Psychiatry, 2021, 36, 1330-1344.	2.7	89
369	In-silico Studies and Biological Activity of Potential BACE-1 Inhibitors. Combinatorial Chemistry and High Throughput Screening, 2021, 24, 729-736.	1.1	1
370	A mixed methods study on the manifestations of behavioural symptoms of dementia among veterans with and without posttraumatic stress disorder. Journal of Advanced Nursing, 2021, 77, 3176-3188.	3.3	8
371	Effect of Cognitive Training in Fully Immersive Virtual Reality on Visuospatial Function and Frontal-Occipital Functional Connectivity in Predementia: Randomized Controlled Trial. Journal of Medical Internet Research, 2021, 23, e24526.	4.3	40
372	Gut Microbiota Changes and Their Correlation with Cognitive and Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 81, 583-595.	2.6	59
373	Blood DNA Methylation Levels in the WNT5A Gene Promoter Region: A Potential Biomarker for Agitation in Subjects with Dementia. Journal of Alzheimer's Disease, 2021, 81, 1601-1611.	2.6	3
374	Risk factors for mild behavioral impairment in non-demented geriatrics: a population-based survey in Taiwan. International Psychogeriatrics, 2021, , 1-9.	1.0	1
375	Exploration of Rapid Automatized Naming and Standard Visual Tests in Prodromal Alzheimer Disease Detection. Journal of Neuro-Ophthalmology, 2021, Publish Ahead of Print, .	0.8	3

#	ARTICLE	IF	CITATIONS
376	System biology and bioinformatics pipeline to identify comorbidities risk association: Neurodegenerative disorder case study. PLoS ONE, 2021, 16, e0250660.	2.5	4
377	Discovery of multifunctional anti-Alzheimer's agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and l ³ -aminobutyric acid transporters. European Journal of Medicinal Chemistry, 2021, 218, 113397.	5.5	14
378	Impact of Dementia-Related Behavioral Symptoms on Healthcare Resource Use and Caregiver Burden: Real-World Data from Europe and the United States. Journal of Alzheimer's Disease, 2021, 81, 1567-1578.	2.6	4
380	Repetitive Transcranial Magnetic Stimulation as an Add-On Treatment for Cognitive Impairment in Alzheimer's Disease and Its Impact on Self-Rated Quality of Life and Caregiver's Burden. Brain Sciences, 2021, 11, 740.	2.3	5
381	Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria. Alzheimer's and Dementia, 2021, 17, 1687-1697.	0.8	8
382	Circular economy monitoring – How to make it apt for biological cycles?. Resources, Conservation and Recycling, 2021, 170, 105563.	10.8	40
383	Quantitative Assessment of Cortical Excitability in Alzheimer's Dementia and Its Association with Clinical Symptoms: A Systematic Review and Meta-Analyses. Journal of Alzheimer's Disease, 2022, 88, 867-891.	2.6	7
384	The Association Between Plasma β -Synuclein (β -syn) Protein, Urinary Alzheimer-Associated Neuronal Thread Protein (AD7c-NTP), and Apolipoprotein Epsilon 4 (ApoE ϵ 4) Alleles and Cognitive Decline in 60 Patients with Alzheimer's Disease Compared with 28 Age-Matched Normal Individuals. Medical Science Monitor, 2021, 27, e932998.	1.1	4
385	Age and gender differences for the behavioral phenotypes of 3xTg alzheimer's disease mice. Brain Research, 2021, 1762, 147437.	2.2	19
386	Feeling valued versus abandoned: Voices of persons who have completed a cognitive assessment. International Journal of Older People Nursing, 2021, 16, e12403.	1.3	4
387	Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer's Disease. Progress in Neurobiology, 2021, 202, 102031.	5.7	46
388	Nighttime Agitation in Persons with Dementia as a Manifestation of Restless Legs Syndrome. Journal of the American Medical Directors Association, 2021, 22, 1410-1414.	2.5	8
389	Novel Biomarkers of Alzheimer's Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress. Clinical Psychopharmacology and Neuroscience, 2021, 19, 423-433.	2.0	11
390	Neuropsychiatric Symptoms in Mild Cognitive Impairment and Dementia Due to AD: Relation With Disease Stage and Cognitive Deficits. Frontiers in Psychiatry, 2021, 12, 707580.	2.6	21
391	Adjunctive Therapy to Manage Neuropsychiatric Symptoms in Moderate and Severe Dementia: Randomized Clinical Trial Using an Outpatient Version of Tailored Activity Program. Journal of Alzheimer's Disease, 2021, 83, 475-486.	2.6	5
392	Microbiota-Gut-Brain Communication in the SARS-CoV-2 Infection. Cells, 2021, 10, 1993.	4.1	17
393	Anxiety and Alzheimer's disease: Behavioral analysis and neural basis in rodent models of Alzheimer's-related neuropathology. Neuroscience and Biobehavioral Reviews, 2021, 127, 647-658.	6.1	31
394	Novel Sulfonamide-Based Carbamates as Selective Inhibitors of BChE. International Journal of Molecular Sciences, 2021, 22, 9447.	4.1	11

#	ARTICLE	IF	CITATIONS
395	Assessing Genetic Overlap and Causality Between Blood Plasma Proteins and Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 83, 1825-1839.	2.6	5
396	Behavioral and Cognitive Response to Selective Serotonin Reuptake Inhibitors in Frontotemporal Lobar Degeneration: A Systematic Review and Meta-analysis. Clinical Neuropharmacology, 2021, 44, 175-183.	0.7	5
397	Early Spatial Memory Impairment in a Double Transgenic Model of Alzheimer's Disease TgF-344 AD. Brain Sciences, 2021, 11, 1300.	2.3	7
398	Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care?. JAMA Neurology, 2021, 78, 1311.	9.0	2
399	Implementation and Evaluation of an Acute Care Multicomponent Intervention for Dementia-Related Behavioral Expressions. Journal of Gerontological Nursing, 2021, 47, 21-30.	0.6	4
400	Pathological methamphetamine exposure triggers the accumulation of neuropathic protein amyloid- β^2 by inhibiting UCHL1. NeuroToxicology, 2021, 86, 19-25.	3.0	4
401	Depression, cognitive reserve markers, and dementia risk in the general population. Aging and Mental Health, 2022, 26, 2006-2013.	2.8	2
402	Antidepressants in Alzheimer's Disease: A Focus on the Role of Mirtazapine. Pharmaceuticals, 2021, 14, 930.	3.8	16
403	A 3-Gene-Based Diagnostic Signature in Alzheimer's Disease. European Neurology, 2022, 85, 6-13.	1.4	7
404	Biodanza as a Nonpharmacological Dance Movement-Based Treatment in Older People With Alzheimer's Disease. Holistic Nursing Practice, 2021, 35, 264-272.	0.7	3
405	Variability in sub-threshold signaling linked to Alzheimer's disease emerges with age and amyloid plaque deposition in mouse ventral CA1 pyramidal neurons. Neurobiology of Aging, 2021, 106, 207-222.	3.1	5
406	5-HT7 receptors in Alzheimer's disease. Neurochemistry International, 2021, 150, 105185.	3.8	12
407	Neuropsychiatric Manifestations Across Neurological Conditions. , 2022, , 167-175.		0
408	Cognitive profile of aging and dementia. , 2022, , 289-305.		0
409	Grupo virtual de apoio aos cuidadores familiares de idosos com demência no contexto da COVID-19. Brazilian Journal of Occupational Therapy, 0, 29, .	0.3	2
410	Examining Depression Symptoms With/Without Coexisting Anxiety Symptoms in Community-Dwelling Persons With Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2021, 36, 153331752199026.	1.9	2
411	Managing Behavioral and Psychological Symptoms of Dementia. Clinics in Geriatric Medicine, 2020, 36, 315-327.	2.6	27
416	NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA: OVERVIEW AND MEASUREMENT CHALLENGES. journal of prevention of Alzheimer's disease, The, 2015, 2, 1-2.	2.7	18

#	ARTICLE	IF	CITATIONS
417	PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCE. <i>Journal of prevention of Alzheimer's disease</i> , The, 2015, 2, 1-6.	2.7	12
418	EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN AN AT-HOME SETTING. <i>Journal of prevention of Alzheimer's disease</i> , The, 2020, 7, 1-8.	2.7	38
419	A FRAMEWORK FOR DEVELOPING PHARMACOTHERAPY FOR AGITATION IN ALZHEIMER'S DISEASE: RECOMMENDATIONS OF THE ISCTM* WORKING GROUP. <i>Journal of prevention of Alzheimer's disease</i> , The, 2020, 7, 1-9.	2.7	5
420	Alzheimer's disease: some pharmacological and non-pharmacological approaches to correcting neuropsychiatric disorders. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2018, 10, 129-134.	1.2	2
421	Neuropsychiatric symptoms and executive function impairments in Alzheimer's disease and vascular dementia: The role of subcortical circuits. <i>Dementia E Neuropsychologia</i> , 2019, 13, 293-298.	0.8	17
422	How non-drug interventions affect the quality of life of patients suffering from progressive cognitive decline and their main caregiver. <i>Aging</i> , 2020, 12, 10754-10771.	3.1	5
423	Neuroimaging Findings Related to Behavioral Disturbances in Alzheimer's Disease: A Systematic Review. <i>Current Alzheimer Research</i> , 2016, 14, 61-75.	1.4	35
424	Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy. <i>Current Neuropharmacology</i> , 2018, 16, 508-518.	2.9	326
425	The Symptoms Targeted for Monitoring in a Web-Based Tracking Tool by Caregivers of People With Dementia and Agitation: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e13360.	4.3	11
426	Multidimensional approach usefulness in early Alzheimer's disease: Advances in clinical practice. <i>Acta Biomedica</i> , 2018, 89, 79-86.	0.3	2
427	The Relationship between Neuropsychiatric Symptoms and Default-Mode Network Connectivity in Alzheimer's Disease. <i>Psychiatry Investigation</i> , 2020, 17, 662-666.	1.6	17
428	What are we trying to prevent in Alzheimer disease?. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 27-34.	3.7	6
429	Pursuing the Complexity of Alzheimer's Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonists. <i>Biomolecules</i> , 2021, 11, 3.	4.0	4
430	Antipsychotics for Neuropsychiatric Symptoms of Dementia: Safety and Efficacy in the Context of Informed Consent. <i>Psychiatric Annals</i> , 2015, 45, .	0.1	6
431	Managing Challenging Behaviors of Dementia in Veterans: Identifying and Changing Activators and Consequences Using STAR-VA. <i>Journal of Gerontological Nursing</i> , 2017, 43, 33-43.	0.6	12
432	Nonpharmacological Strategies Used By Family Caregivers of Persons With Alzheimer's Disease and Related Dementias as Presented in Blogs. <i>Journal of Gerontological Nursing</i> , 2019, 45, 25-35.	0.6	7
433	Preparation and Characterization of Microglia-Like Cells Derived from Rat, Mouse, and Human Bone Marrow Cells for Therapeutic Strategy of Alzheimer's Disease. <i>Journal of Addiction Research & Therapy</i> , 0, s5, .	0.2	3
434	Activated Caspase-3 and Neurodegeneration and Synaptic Plasticity in Alzheimer's Disease. <i>Advances in Alzheimer's Disease</i> , 2015, 04, 63-77.	0.9	12

#	ARTICLE	IF	CITATIONS
435	A Comparison of the Behavioral and Psychological Symptoms of Dementia (BPSD) in Early-Onset and Late-Onset Alzheimer's Disease - A Study from South East Asia (Kashmir, India). Cureus, 2016, 8, e625.	0.5	15
436	Antipsychotic discontinuation after the initiation of selective serotonin reuptake inhibitors therapy for the treatment of behavioral and psychological symptoms associated with dementia. Mental Health Clinician, 2018, 8, 122-126.	1.0	4
437	Antipsychotic use in elderly patients with dementia: Efficacy and safety concerns. Mental Health Clinician, 2014, 4, 170-176.	1.0	5
438	The Positive Effects of Pet Ownership on Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 84, 1669-1675.	2.6	6
439	The doll therapy as a first line treatment for behavioral and psychologic symptoms of dementia in nursing homes residents: a randomized, controlled study. BMC Geriatrics, 2021, 21, 545.	2.7	7
440	Predictors of Caregiver Burden of Patients with Alzheimer Disease Attending Day-Care Centres. International Journal of Environmental Research and Public Health, 2021, 18, 10707.	2.6	4
441	Interactions of comorbid neuropsychiatric subsyndromes with neurodegenerative and cerebrovascular pathologies on cognition. Neurobiology of Aging, 2022, 109, 239-246.	3.1	2
442	Sesamol Attenuates Amyloid Peptide Accumulation and Cognitive Deficits in APP/PS1 Mice: The Mediating Role of the Gut-Brain Axis. Journal of Agricultural and Food Chemistry, 2021, 69, 12717-12729.	5.2	29
443	Dementias and Other Amnestic Disorders. , 2014, , 1-9.		0
444	Neuropsychiatric Symptoms in Alzheimer's Disease Patients: Improving the Diagnosis. , 2014, 04, .		1
445	COMMUNICATION DISORDERS OF ACTIVE MILITARY PERSONNEL WITH TRAUMATIC BRAIN INJURY - A REVIEW STUDY. Military Medical Science Letters (Vojenske Zdravotnicke Listy), 2015, 84, 170-176.	0.5	0
446	Biomarkers in Mild Stages of Alzheimer's disease: Utility in clinical practice and their relation with nutritional and lifestyle factors. Functional Foods in Health and Disease, 2016, 6, 627.	0.6	0
447	Insufficiency of Cellular Energy (ICE) May Precede Neurodegeneration in Alzheimer's Disease and Be Treatable via the Alternative Cellular Energy (ACE) Pathway. Advances in Alzheimer's Disease, 2017, 06, 1-12.	0.9	6
448	Alzheimer Disease. , 2017, , .		0
449	Psychological and Neuropsychological Testing. , 2018, , 81-90.		0
451	A Study on the Status of Psychobehavioral Symptoms in Patients with Alzheimer's Disease. International Journal of Psychiatry and Neurology, 2019, 08, 31-40.	0.1	0
453	Huzurevinde Yaşayan Alzheimer's Hastalarının Yaşadıkları Bireylerin Gıda ve Yaşam Aktivitelerindeki Fonksiyonel Duruma Etki Eden Faktörlerin İncelenmesi. Ergoterapi Ve Rehabilitasyon Dergisi, 2019, 7, 165-170.	0.3	0
454	Behavioral Symptoms of Dementia in Latinos: Pharmacological, Non-pharmacological, and Ethnocultural Healthcare Interventions. , 2020, , 187-203.		0

#	ARTICLE	IF	CITATIONS
455	Immune system and quality of life following aerobic exercise versus resistance exercise training among Alzheimer's. Archives of Asthma Allergy and Immunology, 2020, 4, 003-008.	0.1	0
457	Neuropsychiatric symptoms, quality of life and caregivers' burden in dementia. Open Medicine (Poland), 2020, 15, 905-914.	1.3	8
458	Factors Associated With Behavioral and Psychological Symptoms of Dementia: Prospective Observational Study Using Actigraphy. Journal of Medical Internet Research, 2021, 23, e29001.	4.3	12
459	Late-onset obsessive-compulsive disorder as the initial manifestation of possible behavioural variant Alzheimer's disease. Cognitive Neuropsychiatry, 2022, 27, 11-19.	1.3	4
460	Alzheimer's disease: Causes, treatment & basic science review. IP International Journal of Comprehensive and Advanced Pharmacology, 2021, 6, 108-116.	0.3	0
461	Understanding help-seeking decisions in people with subjective cognitive decline: A systematic review of qualitative studies. Geriatric Nursing, 2021, 42, 1507-1516.	1.9	4
462	Daily garden use and quality of life in persons with advanced dementia living in a nursing home: A feasibility study. Nursing Open, 2021, 8, 1243-1253.	2.4	3
463	Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD). Journal of the American Geriatrics Society, 2021, 69, 955-963.	2.6	9
464	Sleep Behaviors in Persons With Alzheimer's Disease: Associations With Caregiver Sleep and Affect. Journal of Applied Gerontology, 2022, 41, 295-305.	2.0	9
465	Psychiatric Disorders in Dementia. , 2021, , 317-385.		0
466	RhoA/Rock2/Limk1/cofilin1 pathway is involved in attenuation of neuronal dendritic spine loss by paeonol in the frontal cortex of D-galactose and aluminum-induced Alzheimer's disease-like rat model. Acta Neurobiologiae Experimentalis, 2020, 80, 225-244.	0.7	13
467	Block copolymers in Alzheimer's disease therapy: A perspective to revolutionize biomaterials. Journal of Controlled Release, 2021, 340, 271-281.	9.9	17
468	Plasma Total Tau and Neurobehavioral Symptoms of Cognitive Decline in Cognitively Normal Older Adults. Frontiers in Psychology, 2021, 12, 774049.	2.1	4
469	Contribution of Iranian researchers in Alzheimer's disease research: A 10 years scientometric analysis. Journal of Diabetes and Metabolic Disorders, 2021, 20, 2025-2036.	1.9	0
470	Prevalence of mild behavioural impairment domains: a meta-analysis. Psychogeriatrics, 2022, 22, 84-98.	1.2	10
471	Characterization of Alzheimer's Disease-Associated Excitatory Neurons via Single-Cell RNA Sequencing Analysis. Frontiers in Aging Neuroscience, 2021, 13, 742176.	3.4	7
472	Long-term neuropsychiatric symptoms in spontaneous intracerebral haemorrhage survivors. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 232-237.	1.9	11
474	A biopsychosocial interpretation of the Neuropsychiatric Inventory "Nursing Home assessment: reconceptualising psychiatric symptom attributions. BJPsych Open, 2020, 6, e137.	0.7	1

#	ARTICLE	IF	CITATIONS
476	Apathy and related executive syndromes in dementia associated with Parkinson's disease and in Alzheimer's disease. Behavioural Neurology, 2013, 27, 515-22.	2.1	15
477	Pharmacotherapy of neuropsychiatric symptoms of dementia. P and T, 2015, 40, 284-7.	0.9	1
478	Evidence-based Non-pharmacologic Interventions for Managing Neuropsychiatric Symptoms and Mental Health Issues in Residents in Assisted Living. Seniors Housing & Care Journal, 2017, 25, 71-83.	0.5	0
480	Acrolein, an endogenous aldehyde induces Alzheimer's disease-like pathologies in mice: A new sporadic AD animal model. Pharmacological Research, 2022, 175, 106003.	7.1	14
481	Hybrid Feature Selection Framework for the Parkinson Imbalanced Dataset Prediction Problem. Medicina (Lithuania), 2021, 57, 1217.	2.0	13
482	Automated multi-dose dispensing in persons with and without Alzheimer's disease's impacts on pharmacotherapy. European Journal of Clinical Pharmacology, 2022, 78, 513-521.	1.9	0
483	The Moderating Effects of Personal Resources on Caregiver Burden in Carers of Alzheimer's Patients. Frontiers in Psychiatry, 2021, 12, 772050.	2.6	3
484	A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 85, 691-699.	2.6	30
485	In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer's disease phases. Alzheimer's Research and Therapy, 2021, 13, 187.	6.2	29
486	Mild behavioral impairment correlates of cognitive impairments in older adults without dementia: mediation by amyloid pathology. Translational Psychiatry, 2021, 11, 577.	4.8	11
487	Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms. Current Topics in Behavioral Neurosciences, 2021, , 287-317.	1.7	11
488	Psychosis in Alzheimer disease's mechanisms, genetics and therapeutic opportunities. Nature Reviews Neurology, 2022, 18, 131-144.	10.1	62
489	Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets. International Journal of Molecular Sciences, 2022, 23, 1219.	4.1	20
490	A qualitative exploration of living with dementia in supported living environments using a peer researcher approach. Aging and Health Research, 2022, 2, 100055.	1.1	2
491	Exploring how caregivers for people living with dementia use strategies to overcome work system constraints. Applied Ergonomics, 2022, 101, 103689.	3.1	0
494	Clinical Trajectories of Neuropsychiatric Symptoms in Mild-Moderate to Advanced Dementia. Journal of Alzheimer's Disease, 2022, 86, 861-875.	2.6	4
495	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. Frontiers in Psychiatry, 2022, 13, 816465.	2.6	3
496	New Strategies for the Treatment of Neuropsychiatric Disorders Based on Reelin Dysfunction. International Journal of Molecular Sciences, 2022, 23, 1829.	4.1	10

#	ARTICLE	IF	CITATIONS
497	Sleep and dementia. , 2022, , .		0
498	Specific depression dimensions are associated with a faster rate of cognitive decline in older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12268.	2.4	0
499	Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease. Neuropsychopharmacology, 2022, 47, 1128-1136.	5.4	30
500	Targeted Suppression of Lipoprotein Receptor LSR in Astrocytes Leads to Olfactory and Memory Deficits in Mice. International Journal of Molecular Sciences, 2022, 23, 2049.	4.1	3
501	Active music therapy in dementia: results from an open-label trial. Jornal Brasileiro De Psiquiatria, 0, , .	0.7	0
503	Education level is associated with neuropsychiatric symptoms in patients with amnesia-mild cognitive impairment. Psychogeriatrics, 2022, 22, 343-352.	1.2	3
504	Association of Variation in Behavioral Symptoms With Initial Cognitive Phenotype in Adults With Dementia Confirmed by Neuropathology. JAMA Network Open, 2022, 5, e220729.	5.9	11
505	Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography. Journal of Neuropsychiatry and Clinical Neurosciences, 2022, 34, 214-223.	1.8	1
506	Polygenic Risk Score Effectively Predicts Depression Onset in Alzheimer's Disease Based on Major Depressive Disorder Risk Variants. Frontiers in Neuroscience, 2022, 16, 827447.	2.8	4
507	Enhanced Association of Tau Pathology and Cognitive Impairment in Mild Cognitive Impairment Subjects with Behavior Symptoms. Journal of Alzheimer's Disease, 2022, 87, 557-568.	2.6	3
508	Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms (TIME) in home care services: a cluster randomized feasibility trial. BMC Health Services Research, 2022, 22, 415.	2.2	1
509	Design, synthesis and biological evaluation of novel N-phosphorylated and O-phosphorylated tacrine derivatives as potential drugs against Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1012-1022.	5.2	11
510	The Role of Vascular Risk Factors in Biomarker-Based AT(N) Groups: A German-Dutch Memory Clinic Study. Journal of Alzheimer's Disease, 2022, 87, 185-195.	2.6	6
511	Virtual Behavioural Medicine Program: A Novel Model of Care for Neuropsychiatric Symptoms in Dementia1. Journal of Alzheimer's Disease, 2022, 86, 1169-1184.	2.6	2
512	Age-related deficits in working memory in 5xFAD mice in the Hebb-Williams maze. Behavioural Brain Research, 2022, 424, 113806.	2.2	7
513	Towards Defining the Neuroanatomical Basis of Late-Onset Psychiatric Symptoms. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 751-762.	2.3	2
514	stREM2 mediates the associations of minimal depressive symptoms with amyloid pathology in prodromal Alzheimer's disease: The CABLE study. Translational Psychiatry, 2022, 12, 140.	4.8	3
515	Assessments of prolonged effects of desflurane and sevoflurane on motor learning deficits in aged AppNL-G-F/NL-G-F mice. Molecular Brain, 2022, 15, 32.	2.6	2

#	ARTICLE	IF	CITATIONS
517	Alteration of Neural Pathways and Its Implications in Alzheimer's Disease. Biomedicines, 2022, 10, 845.	3.2	8
518	Neuropsychiatric Inventory's Questionnaire Assessed Nighttime Behaviors in Cognitively Asymptomatic Patients with Pathologically Confirmed Alzheimer's Disease Predict More Rapid Cognitive Deterioration. Journal of Alzheimer's Disease, 2022, 86, 1137-1147.	2.6	3
519	Exercise Dosage in Reducing the Risk of Dementia Development: Mode, Duration, and Intensity's A Narrative Review. International Journal of Environmental Research and Public Health, 2021, 18, 13331.	2.6	12
520	The severity of neuropsychiatric symptoms is higher in early-onset than late-onset Alzheimer's disease. European Journal of Neurology, 2022, 29, 957-967.	3.3	16
521	Recent Studies on Berry Bioactives and Their Health-Promoting Roles. Molecules, 2022, 27, 108.	3.8	4
523	Alzheimer's Disease: A Silent Pandemic – A Systematic Review on the Situation and Patent Landscape of the Diagnosis. Recent Patents on Biotechnology, 2022, 16, .	0.8	0
524	Discovery of Novel Drug Candidates for Alzheimer's Disease by Molecular Network Modeling. Frontiers in Aging Neuroscience, 2022, 14, 850217.	3.4	4
525	The Effect of Gut Microbe Dysbiosis on the Pathogenesis of Alzheimer's Disease (AD) and Related Conditions. Current Alzheimer Research, 2022, 19, 274-284.	1.4	3
526	Deep brain stimulation for psychiatric disorders and behavioral/cognitive-related indications: Review of the literature and implications for treatment. Journal of the Neurological Sciences, 2022, 437, 120253.	0.6	3
533	Adult hippocampal neurogenesis and its impairment in Alzheimer's disease. Zoological Research, 2022, 43, 481-496.	2.1	16
534	Transcranial Direct Current Stimulation Enhances Cognitive Function in Patients with Mild Cognitive Impairment and Early/Mid Alzheimer's Disease: A Systematic Review and Meta-Analysis. Brain Sciences, 2022, 12, 562.	2.3	17
535	Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimer's Disease: A Review. Frontiers in Human Neuroscience, 2022, 16, 866434.	2.0	25
536	Daily Physical Activity Patterns as a Window on Cognitive Diagnosis in the Baltimore Longitudinal Study of Aging (BLSA). Journal of Alzheimer's Disease, 2022, 88, 459-469.	2.6	5
537	Shared pathophysiology: Understanding stroke and Alzheimer's disease. Clinical Neurology and Neurosurgery, 2022, 218, 107306.	1.4	9
539	Cognitive Impairment in Alzheimer's and Metabolic Diseases: A Catecholaminergic Hypothesis. Neuroscience, 2022, , .	2.3	6
540	Neurocognitive Disorders. , 2022, , .		0
541	Ameliorative Effects of Phytomedicines on Alzheimer's Patients. Current Alzheimer Research, 2022, 19, 420-439.	1.4	2
542	Ending Choose-Your-Own-Adventure Care for Agitation in Dementia. International Psychogeriatrics, 0, 1-6.	1.0	1

#	ARTICLE	IF	CITATIONS
543	Emerging Neuropsychiatric Symptoms May Represent an Early Manifestation of Preclinical Alzheimer's Disease. <i>Biological Psychiatry</i> , 2022, 92, e1-e3.	1.3	0
544	ATP-sensitive potassium channels: A double-edged sword in neurodegenerative diseases. <i>Ageing Research Reviews</i> , 2022, 80, 101676.	10.9	7
545	A human factors and ergonomics approach to conceptualizing care work among caregivers of people with dementia. <i>Applied Ergonomics</i> , 2022, 104, 103820.	3.1	0
546	The recognition and management of neuropsychiatric symptoms in early Alzheimer's disease: a qualitative study among Dutch memory clinic physicians. <i>Psychogeriatrics</i> , 0, , .	1.2	4
547	Anthocyanin-rich blackcurrant extract improves long-term memory impairment and emotional abnormality in senescence-accelerated mice. <i>Journal of Food Biochemistry</i> , 2022, 46, .	2.9	6
548	Relations of neuropsychiatric symptoms with disease stage, sex, and daily function in mild cognitive impairment and dementia due to Alzheimer's disease: A cross-sectional study. <i>Journal of Psychosomatic Research</i> , 2022, 161, 110994.	2.6	6
549	Neurocognitive health of older adults experiencing homelessness in Oakland, California. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	3
550	Sirtuins and cognition: implications for learning and memory in neurological disorders. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	12
551	Neurologic Music Therapy with a Habilitative Approach for Older Adults with Dementia: A Feasibility Study. <i>Music Therapy Perspectives</i> , 2022, 40, 76-83.	0.5	1
552	Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	16
553	Neuropsychiatric symptoms associated multimodal brain networks in Alzheimer's disease. <i>Human Brain Mapping</i> , 2023, 44, 119-130.	3.6	7
554	Depression in a Patient With Alzheimer Disease. <i>Journal for Nurse Practitioners</i> , 2022, , .	0.8	0
555	Effectiveness of cognitive stimulation therapy (CST) on cognition, quality of life and neuropsychiatric symptoms for patients living with dementia: A meta-analysis. <i>Geriatric Nursing</i> , 2022, 47, 201-210.	1.9	11
556	Effects of chronic vagal nerve stimulation in the treatment of β^2 -amyloid-induced neuropsychiatric symptoms. <i>European Journal of Pharmacology</i> , 2022, 931, 175179.	3.5	5
557	Recent developments in the synthesis of pyridine analogues as a potent anti-Alzheimer's therapeutic leads. , 2023, , 411-444.		1
558	Characterization of Apathy-Like Behaviors in the 5xFAD Mouse Model of Alzheimer's Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
559	Musical Bridges to Memory. <i>Alzheimer Disease and Associated Disorders</i> , 2022, 36, 312-318.	1.3	2
560	Monitoring daily well-being and meaning-making tendencies among adult child working dementia caregivers: validating an experience sampling study protocol. <i>BMC Geriatrics</i> , 2022, 22, .	2.7	0

#	ARTICLE	IF	CITATIONS
561	Pinus halepensis Essential Oil Ameliorates A β ²¹⁻⁴² -Induced Brain Injury by Diminishing Anxiety, Oxidative Stress, and Neuroinflammation in Rats. <i>Biomedicines</i> , 2022, 10, 2300.	3.2	2
562	Boosting amygdaloid GABAergic and neurotrophic machinery via dapagliflozin-enhanced LKB1/AMPK signaling in anxious demented rats. <i>Life Sciences</i> , 2022, 310, 121002.	4.3	8
563	Effects of Reminiscence Therapy on Cognition, Depression and Quality of Life in Elderly People with Alzheimer's Disease: A Systematic Review of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2022, 11, 5752.	2.4	11
564	Roles of neuroligins in central nervous system development: focus on glial neuroligins and neuron neuroligins. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	9
565	Preliminary Validation Study of the French-Quebec Version of the Mild Behavioral Impairment Checklist. <i>Cognitive and Behavioral Neurology</i> , 2023, 36, 9-18.	0.9	2
566	Phyto-therapeutic and nanomedicinal approaches: A new hope for management of Alzheimer's disease. <i>International Journal of Pharmaceutics</i> , 2022, 627, 122213.	5.2	0
567	The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease. <i>Frontiers in Psychiatry</i> , 0, 13, .	2.6	12
568	Sex Modifies the Associations of APOE ϵ 4 with Neuropsychiatric Symptom Burden in Both At-Risk and Clinical Cohorts of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 1571-1588.	2.6	2
569	Blood plasma protein profiles of neuropsychiatric symptoms and related cognitive decline in older people. <i>Journal of Neurochemistry</i> , 2023, 164, 242-254.	3.9	5
570	Targeting Alzheimer's Disease: The Critical Crosstalk between the Liver and Brain. <i>Nutrients</i> , 2022, 14, 4298.	4.1	13
571	May phyto-phenolics alleviate aflatoxins-induced health challenges? A holistic insight on current landscape and future prospects. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	9
572	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	98
573	Improving community health-care systems' early detection of cognitive decline and dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 2375-2381.	0.8	1
574	Ovariectomy-induced hormone deprivation aggravates A β ²¹⁻⁴² deposition in the basolateral amygdala and cholinergic fiber loss in the cortex but not cognitive behavioral symptoms in a triple transgenic mouse model of Alzheimer's disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	3
575	Tactile stimulation improves cognition, motor, and anxiety-like behaviors and attenuates the Alzheimer's disease pathology in adult APP ^{NL-GF/NL-GF} mice. <i>Synapse</i> , 2023, 77, .	1.2	2
576	The Effect of Agomelatine in Behavioral and Psychological Symptoms of Dementia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022, 20, 701-714.	2.0	1
577	The Willingness to Help People With Dementia Symptoms Among Four Occupation Practitioners in Macao. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2022, 37, 153331752211391.	1.9	0
578	Differential Gene Expression and DNA Methylation in the Risk of Depression in LOAD Patients. <i>Biomolecules</i> , 2022, 12, 1679.	4.0	1

#	ARTICLE	IF	CITATIONS
579	The effectiveness of non-pharmacological interventions using information and communication technologies for behavioral and psychological symptoms of dementia: A systematic review and meta-analysis. <i>International Journal of Nursing Studies</i> , 2023, 138, 104392.	5.6	12
580	Behavioral and psycho-social impairments among people living with dementia and their management by caregivers in South-Western Uganda: a qualitative study. <i>Aging and Mental Health</i> , 2023, 27, 1938-1945.	2.8	0
581	Design, synthesis, and preliminary evaluation of [18F]-aryl fluoro-sulfates PET radiotracers via SuFEx methods for β -amyloid plaques in Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 75, 117087.	3.0	3
582	Light Therapy to Improve Sleep Quality in Older Adults Living in Residential Long-Term Care: A Systematic Review. <i>Journal of the American Medical Directors Association</i> , 2023, 24, 65-74.e1.	2.5	3
583	Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer's disease: relevance for precision medicine in neurodegenerative diseases. <i>Ageing Research Reviews</i> , 2023, 84, 101819.	10.9	9
584	Exercise interventions ameliorate neuropsychiatric symptoms in dementia: A meta-analysis. <i>Mental Health and Physical Activity</i> , 2023, 24, 100496.	1.8	0
585	Upregulation of Ca ²⁺ -binding proteins contributes to VTA dopamine neuron survival in the early phases of Alzheimer's disease in Tg2576 mice. <i>Molecular Neurodegeneration</i> , 2022, 17, .	10.8	16
586	Effect of a multimodal non-pharmacological intervention on older people with dementia: a single-case experimental design study. <i>BMC Geriatrics</i> , 2022, 22, .	2.7	1
587	Healthcare use patterns before Alzheimer's disease and related diseases identification and future healthcare trajectory. <i>International Journal of Geriatric Psychiatry</i> , 2023, 38, .	2.7	0
588	The role of ethnicity, biological sex, and psychotropic agents in early and late onset Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	0
589	“I Will Be Healthy” Ideal Self in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 775-781.	2.2	0
590	Purinergic signaling in cognitive impairment and neuropsychiatric symptoms of Alzheimer's disease. <i>Neuropharmacology</i> , 2023, 226, 109371.	4.1	9
591	Antidepressants as a potential candidate to reduce microglia activation in neurodegenerative diseases. A systematic review and meta-analysis of preclinical studies. <i>Journal of Affective Disorders Reports</i> , 2023, 11, 100465.	1.7	0
592	A Review on Phyto-Therapeutic Approaches in Alzheimer's Disease. <i>Journal of Functional Biomaterials</i> , 2023, 14, 50.	4.4	5
593	Gut Microbiota, Alzheimer and Psychiatric Diseases: Unveiling the Relationships and Treatment Options. <i>Healthy Ageing and Longevity</i> , 2023, , 279-333.	0.2	0
594	Ethics in Geriatric Mental Health. , 2022, , .		0
595	Dementia and Mild Neurocognitive Disorders. , 2022, , .		0
596	Schizophrenia Spectrum and Other Psychotic Disorders. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
597	Genomics in Geriatric Psychiatry. , 2022, , .		0
599	Individual and Group Psychotherapy. , 2022, , .		0
600	Sexuality and Aging. , 2022, , .		0
601	Use of the Laboratory in the Diagnostic Workup of Older Adults. , 2022, , .		0
602	Anxiety, Obsessive-Compulsive, and Trauma-Related Disorders. , 2022, , .		1
603	Working With Families of Older Adults. , 2022, , .		0
604	Somatic Symptom and Related Disorders. , 2022, , .		0
606	Neuropsychological Assessment of Late-Life Cognitive Disorders. , 2022, , .		0
607	Sleep and Circadian Rhythm Sleep-Wake Disorders. , 2022, , .		0
608	Bipolar and Related Disorders. , 2022, , .		0
609	The Psychiatric Interview of Older Adults. , 2022, , .		0
611	Substance-Related and Addictive Disorders. , 2022, , .		0
613	Electroconvulsive Therapy and Other Forms of Brain Stimulation. , 2022, , .		0
614	Depressive Disorders. , 2022, , .		0
615	Physiological and Clinical Considerations of Geriatric Patient Care. , 2022, , .		0
616	Epidemiology of Psychiatric Disorders in Later Life. , 2022, , .		0
618	Use of Technology in Geriatric Psychiatry. , 2022, , .		0
619	Agitation in Older Adults. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
620	Clinical Psychiatry in the Nursing Home. , 2022, , .		0
622	Kan bruk av atferd- og dÅgnrytmeregistreringsskjema predikere aggresjon og irritasjon hos pasienter innlagt i en alderspsykiatrisk dÅgnavdeling?. Nordisk Sygeplejeforskning, 2023, 13, 1-23.	0.2	0
623	A Review on Recent Approaches on Molecular Docking Studies of Novel Compounds Targeting Acetylcholinesterase in Alzheimer Disease. Molecules, 2023, 28, 1084.	3.8	16
624	Behavioral and Psychological Symptoms of Dementia: Prevalence, Symptom Severity, and Caregiver Distress in South-Western Ugandaâ€”A Quantitative Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2023, 20, 2336.	2.6	1
625	Microglial Activation in Metal Neurotoxicity: Impact in Neurodegenerative Diseases. BioMed Research International, 2023, 2023, 1-27.	1.9	8
627	Pharmacologic treatment of depression in Alzheimerâ€™s disease. International Clinical Psychopharmacology, 2023, 38, 81-88.	1.7	4
628	Human tau-overexpressing mice recapitulate brainstem involvement and neuropsychiatric features of early Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2023, 11, .	5.2	6
629	Molecular mechanisms of ferroptosis and their involvement in brain diseases. , 2023, 244, 108373.		42
630	Characterization of apathy-like behaviors in the 5xFAD mouse model of Alzheimerâ€™s disease. Neurobiology of Aging, 2023, 126, 113-122.	3.1	4
631	The role of dopamine in NLRP3 inflammasome inhibition: Implications for neurodegenerative diseases. Ageing Research Reviews, 2023, 87, 101907.	10.9	12
632	An Intervention on Anxiety Symptoms in Moderate Alzheimerâ€™s Disease through Virtual Reality: A Feasibility Study and Lessons Learned. International Journal of Environmental Research and Public Health, 2023, 20, 2727.	2.6	5
633	Impact of behavioral and psychological symptoms of dementia (BPSD) in institutionalized people. MOJ Gerontology & Geriatrics, 2019, 4, 233-239.	0.1	0
634	Intranasal Lipid Nanoparticles Containing Bioactive Compounds Obtained from Marine Sources to Manage Neurodegenerative Diseases. Pharmaceuticals, 2023, 16, 311.	3.8	2
635	Physical Exercise as a Nonpharmacological Intervention for the Treatment of Neuropsychiatric Symptoms in Persons With Dementia. Alzheimer Disease and Associated Disorders, 2023, 37, 73-81.	1.3	0
636	Behavioural subphenotypes and their anatomic correlates in neurodegenerative disease. Brain Communications, 2023, 5, .	3.3	3
637	Neuropsychiatric Manifestations in Alzheimerâ€™s Disease Patients: Genetics and Treatment Options. CNS and Neurological Disorders - Drug Targets, 2023, 22, .	1.4	0
638	Quality of Nursing Homes Among ADRD Residents Newly Admitted From the Community: Does Race Matter?. Journal of the American Medical Directors Association, 2023, , .	2.5	0
640	LIM Kinases, LIMK1 and LIMK2, Are Crucial Node Actors of the Cell Fate: Molecular to Pathological Features. Cells, 2023, 12, 805.	4.1	3

#	ARTICLE	IF	CITATIONS
641	Assessing the Role of Past Depression in Patients with Mild Cognitive Impairment, with and without Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 1219-1227.	2.6	0
642	Discrepancy Between Patient and Caregiver Estimate of Apathy Predicts Dementia in Patients with Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2023, , 1-12.	2.6	0
643	The Effects of Light Therapy on Sleep, Agitation and Depression in People With Dementia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2023, 38, 153331752311606.	1.9	5
647	Influence of affective states on informant impression of neuropsychiatric symptoms in people living with MCI. <i>Aging and Mental Health</i> , 2023, 27, 2128-2133.	2.8	0
648	Female perspective: the burden of Alzheimer's disease and other dementias in China from 1990 to 2019 and prediction of their prevalence up to 2044. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	0
649	Effects of cognitive stimulation therapy on patients with dementia: An umbrella review of systematic reviews and meta-analyses. <i>Experimental Gerontology</i> , 2023, 177, 112197.	2.8	0
651	The effects of active music interventions on cognitive function and neuropsychiatric symptoms in patients with dementia: A systematic review and meta-analysis. <i>Musicae Scientiae</i> , 2024, 28, 112-130.	2.9	0
652	Research Models to Study Ferroptosis's Impact in Neurodegenerative Diseases. <i>Pharmaceutics</i> , 2023, 15, 1369.	4.5	5
653	The reporting of neuropsychiatric symptoms in electronic health records of individuals with Alzheimer's disease: a natural language processing study. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	6.2	2
654	Pilot Study of Second-Generation DNA Methylation Epigenetic Markers in Relation to Cognitive and Neuropsychiatric Symptoms in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2023, 93, 1563-1575.	2.6	2
655	Age-Dependent Alterations in Platelet Mitochondrial Respiration. <i>Biomedicines</i> , 2023, 11, 1564.	3.2	2
656	Malnutrition and neuropsychiatric symptoms in dementia: the Cache County Dementia Progression Study. <i>International Psychogeriatrics</i> , 2023, 35, 653-663.	1.0	2
657	Hepatic Oxi-Inflammation and Neophobia as Potential Liver-Brain Axis Targets for Alzheimer's Disease and Aging, with Strong Sensitivity to Sex, Isolation, and Obesity. <i>Cells</i> , 2023, 12, 1517.	4.1	3
658	Offering Out-World Experiences to Dementia In-patients through Virtual Reality: Mixed-Method Design (Preprint). <i>JMIR Aging</i> , 0, , .	3.0	0
659	Autophagy Mechanisms for Brain Recovery. Keep It Clean, Keep It Alive. <i>Contemporary Clinical Neuroscience</i> , 2023, , 41-76.	0.3	0
660	Neurodegenerative Disorders/Dementia. , 2023, , 215-226.		0
662	Associations between neuropsychiatric symptoms of affective and vegetative domains and brain morphology in aging people with mild cognitive impairment and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2023, 38, .	2.7	0
663	Improved frontal activity on functional near-infrared spectroscopy after improvement of apathy symptoms in a patient with Alzheimer's disease. <i>Psychogeriatrics</i> , 2023, 23, 725-727.	1.2	0

#	ARTICLE	IF	CITATIONS
664	The role of sex differences in depression in pathologically defined Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	3.4	1
665	Outcomes and Factors Affecting Transcranial Direct Current Stimulation in Alzheimer's Disease Patients: A Systematic Review. <i>Current Alzheimer Research</i> , 2023, 20, 250-266.	1.4	2
666	Unveiling the Enigma: Exploring Risk Factors and Mechanisms for Psychotic Symptoms in Alzheimer's Disease through Electronic Medical Records with Deep Learning Models. <i>Pharmaceuticals</i> , 2023, 16, 911.	3.8	5
667	The SARS-CoV-2 vaccination rate and hesitation in Shanghai older adults with dementia. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	0
668	Alzheimer's disease: an epidemiological analysis over the number of hospitalizations and deaths in Brazil. <i>Arquivos De Neuro-Psiquiatria</i> , 2023, 81, 577-584.	0.8	0
669	Fatigue in Alzheimer's disease: biological basis and clinical management—a narrative review. <i>Aging Clinical and Experimental Research</i> , 2023, 35, 1981-1989.	2.9	2
670	APOE Gene Associated with Dementia-Related Traits, Depression, and Anxiety in the Hispanic Population. <i>Genes</i> , 2023, 14, 1405.	2.4	1
671	Escapade Dance Serious Game: Designing a Therapeutic Tool for Elderly with Mild Cognitive Impairment. <i>Lecture Notes in Computer Science</i> , 2023, , 222-236.	1.3	0
672	Prevalence and impact of neuropsychiatric symptoms in normal aging and neurodegenerative syndromes: A population-based study from Latin America. <i>Alzheimer's and Dementia</i> , 0, , .	0.8	0
673	Classification of Alzheimer's Disease Using Maximal Information Coefficient-Based Functional Connectivity with an Extreme Learning Machine. <i>Brain Sciences</i> , 2023, 13, 1046.	2.3	0
674	Temporal patterns of the burden of Alzheimer's disease and their association with <scp>Sociodemographic</scp> Index in countries with varying rates of aging 1990–2019. <i>Aging Medicine (Milton (N S W))</i> , 2023, 6, 281-289.	2.1	0
675	A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders. <i>Brain Sciences</i> , 2023, 13, 1061.	2.3	1
676	An Update on Apathy in Alzheimer's Disease. <i>Geriatrics (Switzerland)</i> , 2023, 8, 75.	1.7	0
677	Neuropsychiatric Symptoms of Alzheimer's Disease: An Anatomic-Genetic Framework for Treatment Development. <i>Journal of Alzheimer's Disease</i> , 2023, 95, 53-68.	2.6	1
678	Emotion Regulation in Dementia Caregiving: The Role of Neuropsychiatric Symptoms and Attachment Orientation. <i>Journal of Geriatric Psychiatry and Neurology</i> , 0, , .	2.3	0
679	Could the Urease of the Gut Bacterium <i>Proteus mirabilis</i> Play a Role in the Altered Gut–Brain Talk Associated with Parkinson's Disease?. <i>Microorganisms</i> , 2023, 11, 2042.	3.6	2
680	Exploring the relationship between patient-relevant outcomes and Alzheimer's disease progression assessed using the clinical dementia rating scale: a systematic literature review. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	0
682	Understanding neuropsychiatric symptoms in Alzheimer's disease: challenges and advances in diagnosis and treatment. <i>Frontiers in Neuroscience</i> , 0, 17, .	2.8	4

#	ARTICLE	IF	CITATIONS
683	Palliative care for persons with late-stage Alzheimer's and related dementias and their caregivers: protocol for a randomized clinical trial. <i>Trials</i> , 2023, 24, .	1.6	0
684	Comparison of dance and aerobic exercise on cognition and neuropsychiatric symptoms in sedentary older adults with cognitive impairment. <i>European Geriatric Medicine</i> , 0, , .	2.8	1
685	Ginsenoside Rg1, lights up the way for the potential prevention of Alzheimer's disease due to its therapeutic effects on the drug-controllable risk factors of Alzheimer's disease. <i>Journal of Ethnopharmacology</i> , 2024, 318, 116955.	4.1	1
686	Cognitive Deficits and Alzheimer's Disease-Like Pathologies in the Aged Chinese Tree Shrew. <i>Molecular Neurobiology</i> , 0, , .	4.0	0
687	Simultaneous Intranasal Codelivery of Donepezil and Memantine in a Nanocolloidal Carrier: Optimization, Pharmacokinetics, and Pharmacodynamics Studies. <i>Molecular Pharmaceutics</i> , 2023, 20, 4714-4728.	4.6	1
688	Lipid Profiling in Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 281-287.	1.6	0
689	Neuropsychiatric symptoms in people living with dementia receiving home health services. <i>Journal of the American Geriatrics Society</i> , 2023, 71, 3865-3873.	2.6	1
690	Neuropsychiatric Symptoms and Trajectories of Dependence and Cognition in a Sample of Community-dwelling Older Adults with Dementia. <i>Current Alzheimer Research</i> , 2023, 20, 409-419.	1.4	0
691	Improving Alzheimer Diagnoses With An Interpretable Deep Learning Framework: Including Neuropsychiatric Symptoms. <i>Neuroscience</i> , 2023, 531, 86-98.	2.3	0
692	Health-related quality of life and mild behavioral impairment in older adults without dementia. <i>International Journal of Geriatric Psychiatry</i> , 2023, 38, .	2.7	0
693	Physical Exercise as Disease-Modifying Alternative against Alzheimer's Disease: A Gut-Muscle-Brain Partnership. <i>International Journal of Molecular Sciences</i> , 2023, 24, 14686.	4.1	2
694	Diagnostic performance of MRI radiomics for classification of Alzheimer's disease, mild cognitive impairment, and normal subjects: a systematic review and meta-analysis. <i>Aging Clinical and Experimental Research</i> , 2023, 35, 2333-2348.	2.9	1
695	Psychiatric Disorders Before and After Dementia Diagnosis. <i>JAMA Network Open</i> , 2023, 6, e2338080.	5.9	0
696	Combining donepezil and memantine via mannosylated PLGA nanoparticles for intranasal delivery: Characterization and preclinical studies. , 2023, 154, 213663.		1
697	Microbiota from Alzheimer's patients induce deficits in cognition and hippocampal neurogenesis. <i>Brain</i> , 2023, 146, 4916-4934.	7.6	14
698	ALZHEIMER HASTALIĞINDA İNOS 5-NH ₂ -B ₆ T ₄ -RLERİNİN UMUT VERİCİ ROLÜ. <i>Ankara Üniversitesi Eczacılık Fakültesi Dergisi</i> , 2024, 48, 4-4.	0.1	0
699	Common Neuropsychiatric Symptoms in Alzheimer's Disease, Mild Cognitive Impairment, and Subjective Memory Complaints: A Unified Framework. <i>Current Alzheimer Research</i> , 2023, 20, .	1.4	0
700	Advancements in Synthesis and Application of 1,5-Benzodiazepines a Privileged Scaffold with a Wide Scope of Bioactivities. <i>Current Organic Chemistry</i> , 2023, 27, .	1.6	0

#	ARTICLE	IF	CITATIONS
701	Analysis of Concomitant Medications Prescribed with Antipsychotics to Patients with Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2023, 52, 222-231.	1.5	0
702	"Let's just die together, Mom": Family caregivers' responses to caring for elderly people with dementia. <i>Kontakt</i> , 0, , .	0.2	0
703	Pathogenesis of Depression in Alzheimer's Disease. <i>Neurochemical Research</i> , 2024, 49, 548-556.	3.3	1
704	The Role of RIN3 Gene in Alzheimer's Disease Pathogenesis: a Comprehensive Review. <i>Molecular Neurobiology</i> , 0, , .	4.0	0
705	Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	6.2	1
706	Alzheimer's disease and microorganisms: the non-coding RNAs crosstalk. <i>Frontiers in Cellular Neuroscience</i> , 0, 17, .	3.7	0
707	Exercise Intervention for Alzheimer's Disease: Unraveling Neurobiological Mechanisms and Assessing Effects. <i>Life</i> , 2023, 13, 2285.	2.4	0
708	The impact of mild behavioral impairment on the prognosis of geriatric depression: preliminary results. <i>International Clinical Psychopharmacology</i> , 0, , .	1.7	1
710	Neuropsychiatric Symptoms and In Vivo Alzheimer's Biomarkers in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2023, 96, 1827-1836.	2.6	0
711	Integrated network pharmacology and comprehensive bioinformatics identifying the mechanisms and molecular targets of Jieyu Anshen Granules for treating comorbidity with Alzheimer's disease and depression. <i>Arabian Journal of Chemistry</i> , 2024, 17, 105485.	4.9	0
713	A Review on Machine Learning and Deep Learning Based Approaches in Detection and Grading of Alzheimer's Disease. <i>Communications in Computer and Information Science</i> , 2024, , 1-13.	0.5	0
714	Moderate and vigorous leisure time physical activity in older adults and Alzheimer's disease-related mortality in the USA: a dose-response, population-based study. <i>The Lancet Healthy Longevity</i> , 2023, 4, e703-e710.	4.6	0
715	Mild Behavioral Impairment. <i>GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry</i> , 0, , .	0.5	0
716	Correlation between white matter hyperintensity and delusional symptoms in Alzheimer's disease. <i>BMC Psychiatry</i> , 2023, 23, .	2.6	0
717	Cerebrospinal fluid levels of hypothalamic-pituitary-adrenal axis hormones in MCI and dementia due to Alzheimer's disease: a systematic review. <i>Dementia & Neuropsychologia</i> , 0, 17, .	0.8	0
718	Postweaning intermittent sleep deprivation enhances defensive attack in adult female mice via the microbiota-gut-brain axis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2024, 130, 110915.	4.8	0
719	Targeting glycogen synthase kinase-3 β for Alzheimer's disease: Recent advances and future Prospects. <i>European Journal of Medicinal Chemistry</i> , 2024, 265, 116065.	5.5	1
720	Alzheimer's Disease and Drug Targets. , 2023, , 3-16.		0

#	ARTICLE	IF	CITATIONS
721	Generation and Characterization of a Human-Derived and Induced Pluripotent Stem Cell (iPSC) Line from an Alzheimer's Disease Patient with Neuropsychiatric Symptoms. <i>Biomedicines</i> , 2023, 11, 3313.	3.2	0
722	CUIDADOS PALIATIVOS NA DOENÇA DE ALZHEIMER: RELATO DE EXPERIÊNCIA. , 2023, 3, 27675-27696.		0
723	Factors Related to Higher and Lower Performance and Adherence in STAR-VA Program Sustainment in Veterans Administration (VA) Community Living Centers (CLCs). <i>Journal of the American Medical Directors Association</i> , 2023, , .	2.5	0
724	Amyloid Pathology Modulates the Associations of Neuropsychiatric Symptoms with Cognitive Impairments and Neurodegeneration in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , 2023, , 1-14.	2.6	0
725	Presence and Characteristics of Behavioral and Psychological Symptoms in Subacute Stroke Patients with Cognitive Impairment. <i>Behavioural Neurology</i> , 2023, 2023, 1-8.	2.1	0
726	Diagnosis Framework for Probable Alzheimer's Disease and Mild Cognitive Impairment Based on Multi-Dimensional Emotion Features. <i>Journal of Alzheimer's Disease</i> , 2024, 97, 1125-1137.	2.6	0
727	Distinguishing features of depression in dementia from primary psychiatric disease. <i>Discover Mental Health</i> , 2024, 4, .	2.0	1
728	Monitoring synaptic pathology in Alzheimer's disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives. <i>Molecular Psychiatry</i> , 0, , .	7.9	0
729	FcγRIIb Exacerbates LPS-Induced Neuroinflammation by Binding with the Bridging Protein DAP12 and Promoting the Activation of PI3K/AKT Signaling Pathway in Microglia. <i>Journal of Inflammation Research</i> , 0, Volume 17, 41-57.	3.5	0
730	Improving preclinical to clinical translation of cognitive function for aging-related disorders: the utility of comprehensive touchscreen testing batteries in common marmosets. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 2024, 24, 325-348.	2.0	2
732	Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History. <i>Journal of Clinical Medicine</i> , 2024, 13, 536.	2.4	0
733	The Relationship Between First Presenting Neuropsychiatric Symptoms in Older Adults and Autopsy-Confirmed Memory Disorders. <i>American Journal of Geriatric Psychiatry</i> , 2024, , .	1.2	0
734	Digging into the intrinsic capacity concept: Can it be applied to Alzheimer's disease?. <i>Progress in Neurobiology</i> , 2024, 234, 102574.	5.7	0
735	Facial emotion recognition is associated with executive functions and depression scores, but not staging of dementia, in mild-to-moderate Alzheimer's disease. <i>Brain and Behavior</i> , 2024, 14, .	2.2	0
736	Intranasal administration of silibinin-loaded pullulan acetate nanocarriers: A pH-responsive approach for brain targeting in Alzheimer's disease. <i>Journal of Drug Delivery Science and Technology</i> , 2024, 93, 105448.	3.0	0
737	Behavioral and Neurophysiological Implications of Pathological Human Tau Expression in Serotonin Neurons. <i>ACS Chemical Neuroscience</i> , 2024, 15, 932-943.	3.5	0
738	Visualization analysis of exercise intervention on Alzheimer disease based on bibliometrics: Trends, hotspots and topics. <i>Medicine (United States)</i> , 2023, 102, e36347.	1.0	0
740	Associations of Frailty with Neuropsychiatric Symptoms of Alzheimer's Disease: A Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2024, 98, 629-642.	2.6	0

#	ARTICLE	IF	CITATIONS
741	The Effect of Apathy and Depressive Syndromes on Functional Outcomes in Alzheimer's Disease. Journal of Alzheimer's Disease, 2024, 98, 579-591.	2.6	0
742	Redox-associated changes in healthy individuals at risk of Alzheimer's disease. A ten-year follow-up study. Free Radical Biology and Medicine, 2024, 215, 56-63.	2.9	0
743	Neuroprotective effects of Shenghui decoction via inhibition of the JNK/p38 MAPK signaling pathway in an Aβ-induced zebrafish (Danio rerio) model of Alzheimer's disease. Journal of Ethnopharmacology, 2024, 328, 117993.	4.1	0
744	Association between CNS-active drugs and risk of Alzheimer's and age-related neurodegenerative diseases. Frontiers in Psychiatry, 0, 15, .	2.6	0
745	The longitudinal relationship between levels of cognitively stimulating leisure activity and positive and negative affect among older adults with ¹¹MCI. Psychogeriatrics, 2024, 24, 369-381.	1.2	0
746	Dementia Prevention and Treatment. JAMA Internal Medicine, 2024, 184, 563.	5.1	0
747	Acanthopanax senticosus improves cognitive impairment in Alzheimer's disease by promoting the phosphorylation of the MAPK signaling pathway. Frontiers in Immunology, 0, 15, .	4.8	0
748	Prevalence of mild behavioural impairment and its association with cognitive and functional impairment in normal cognition, mild cognitive impairment, and mild ¹¹Alzheimer's dementia. Psychogeriatrics, 2024, 24, 555-564.	1.2	0
749	Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease. Biomedicine and Pharmacotherapy, 2024, 173, 116399.	5.6	0
750	Unraveling the dual role of ADAM10: Bridging the gap between cancer and Alzheimer's disease. Mechanisms of Ageing and Development, 2024, 219, 111928.	4.6	0
752	PET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [¹¹ C]MK-6884: Quantification with kinetic modeling and receptor occupancy by CVL-231 (emraclidine), a novel positive allosteric modulator. Journal of Cerebral Blood Flow and Metabolism, 0, , .	4.3	0